MCID: HYP082
MIFTS: 51

Hypopharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hypopharynx Cancer

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 11 14 16
Hypopharyngeal Cancer 11 19 53 71 75
Malignant Neoplasm of Hypopharynx 11 31
Hypopharyngeal Neoplasms 43 71
Hypopharyngeal Carcinoma 16 71
Malignant Tumour of Hypopharynx 11
Malignant Hypopharyngeal Tumor 11
Malignant Tumor of Hypopharynx 11

Classifications:



External Ids:

Disease Ontology 11 DOID:8533
ICD9CM 34 148 148.3
MeSH 43 D007012
NCIt 49 C7190
SNOMED-CT 68 93831006 93968005
ICD10 31 C13 C13.2 C13.9
UMLS 71 C0020627 C0153398 C0496770 more

Summaries for Hypopharynx Cancer

Disease Ontology: 11 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary: Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to laryngeal benign neoplasm and larynx cancer. An important gene associated with Hypopharynx Cancer is MIR489 (MicroRNA 489), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Nicotinamide and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include hypopharynx, lymph node and tongue, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia: 75 Hypopharyngeal cancer is a disease in which malignant cells grow in the hypopharynx (also known as the... more...

Related Diseases for Hypopharynx Cancer

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 418, show less)
# Related Disease Score Top Affiliating Genes
1 laryngeal benign neoplasm 30.4 TP53 EGFR CDKN2A CAGE1
2 larynx cancer 30.3 TP53 NME1 MIR143 EGFR BCL2
3 lip and oral cavity cancer 30.3 TP53 EGFR CDKN2A CDH1
4 in situ carcinoma 30.2 TP53 EGFR CDKN2A CDH1 AKT1
5 oropharynx cancer 30.1 TP53 EGFR CDKN2A CDH1 CD274 BCL2
6 spinal cord disease 30.0 TP53 EGFR CDKN2A AKT1
7 squamous cell carcinoma 29.9 TP53 STAT3 NME1 EGFR CDKN2A CDH1
8 carcinosarcoma 29.9 TP53 EGFR CDKN2A CDH1 CD274
9 adenoma 29.7 TP53 CDKN2A CDH1 BCL2 AKT1
10 keratoacanthoma 29.6 TP53 STAT3 EGFR CDH1 BCL2
11 laryngeal squamous cell carcinoma 29.6 TP53 STAT3 NME1 EGFR CDKN2A CDH1
12 papilloma 29.5 TP53 EGFR CDKN2A CDH1 BCL2 AKT1
13 squamous cell carcinoma, head and neck 29.5 TP53 STAT3 MIR143 MET EGFR CDKN2A
14 b-cell lymphoma 29.4 TP53 STAT3 CDKN2A CD274 BCL2 AKT1
15 amyotrophic lateral sclerosis 1 29.2 TP53 STAT3 NGFR MIR143 BCL2 AKT1
16 esophageal cancer 29.2 TP53 STAT3 NME1 MIR143 EGFR CDKN2A
17 nasopharyngeal carcinoma 29.2 TP53 STAT3 NME1 MIR143 EGFR CDKN2A
18 lung cancer susceptibility 3 29.0 TP53 STAT3 MIR143 MET EGFR CDKN2A
19 diabetes mellitus 28.9 TP53 STAT3 MIR143 EGFR CDKN2A CD274
20 head and neck cancer 28.8 TP53 STAT3 PRB4 MIR143 EGFR CDKN2A
21 gastric cancer 28.6 TP53 STAT3 SNHG7 NME1 MIR143 MET
22 tonsillar pillar cancer 10.4 EGFR CDKN2A
23 endometrial squamous cell carcinoma 10.3 TP53 CDKN2A
24 penis basal cell carcinoma 10.3 CDKN2A CDH1
25 papillary squamous carcinoma 10.3 EGFR CDKN2A
26 neurofibroma 10.3 TP53 EGFR CDKN2A
27 tetraploidy 10.3 TP53 NGFR
28 frontal lobe neoplasm 10.3 TP53 EGFR
29 idh-wildtype glioblastoma 10.3 TP53 EGFR CDKN2A
30 adult malignant schwannoma 10.3 TP53 EGFR CDKN2A
31 mixed glioma 10.3 TP53 EGFR CDKN2A
32 cervical adenocarcinoma 10.3 TP53 NME1 CDKN2A
33 adenocarcinoma in situ 10.3 TP53 EGFR CDKN2A
34 urethra transitional cell carcinoma 10.3 TP53 EGFR
35 diffuse astrocytoma 10.3 TP53 EGFR CDKN2A
36 mucinous adenocarcinoma 10.3 TP53 EGFR CDKN2A
37 bizarre leiomyoma 10.3 TP53 CDKN2A
38 lung sarcomatoid carcinoma 10.3 MET EGFR CD274
39 early invasive cervical adenocarcinoma 10.3 CDKN2A BCL2
40 penile benign neoplasm 10.3 TP53 CDKN2A CD274
41 lobular neoplasia 10.3 TP53 EGFR CDH1
42 pleomorphic carcinoma 10.3 TP53 EGFR CD274
43 sinus cancer 10.2
44 peritoneal mesothelioma 10.2 TP53 CDKN2A CD274
45 anaplastic oligodendroglioma 10.2 TP53 EGFR CDKN2A
46 good syndrome 10.2 TP53 EGFR CD274
47 thoracic benign neoplasm 10.2 TP53 EGFR CDH1
48 inflammatory myofibroblastic tumor 10.2 TP53 MET EGFR
49 breast benign neoplasm 10.2 TP53 EGFR CDH1
50 ampulla of vater cancer 10.2 TP53 EGFR CDKN2A
51 bilateral breast cancer 10.2 TP53 CDKN2A CDH1
52 follicular adenoma 10.2 NME1 MET CDH1
53 postcricoid region cancer 10.2
54 aryepiglottic fold cancer 10.2
55 ovarian stromal hyperthecosis 10.2 CDH1 BCL2
56 bronchiolo-alveolar adenocarcinoma 10.2 TP53 EGFR CDH1
57 lung carcinoma in situ 10.2 TP53 EGFR AKT1
58 oral submucous fibrosis 10.2 TP53 EGFR CDH1
59 melanoma in congenital melanocytic nevus 10.2 TP53 NGFR CDKN2A
60 lung benign neoplasm 10.2 TP53 MET EGFR CDKN2A
61 gastric adenosquamous carcinoma 10.2 TP53 CAGE1
62 myxofibrosarcoma 10.2 TP53 CDKN2A CD274
63 atypical teratoid rhabdoid tumor 10.2 TP53 EGFR CDKN2A
64 hypertrophy of breast 10.2 TP53 EGFR AKT1
65 aplasia of lacrimal and salivary glands 10.2
66 pharynx cancer 10.2
67 pyriform sinus cancer 10.2
68 giant cell glioblastoma 10.2 TP53 EGFR CDKN2A
69 salivary gland carcinoma 10.2 TP53 MET EGFR CDKN2A
70 endocervical adenocarcinoma 10.2 TP53 CDKN2A CD274
71 spinal cord oligodendroglioma 10.2 TP53 EGFR
72 esophagus verrucous carcinoma 10.2 TP53 EGFR CDKN2A CDH1
73 verrucous carcinoma 10.2 TP53 EGFR CDKN2A CDH1
74 squamous cell papilloma 10.2 TP53 CDKN2A
75 keratinizing squamous cell carcinoma 10.2 TP53 EGFR CDKN2A CDH1
76 adenoid squamous cell carcinoma 10.2 TP53 CDH1
77 gastroesophageal junction adenocarcinoma 10.2 TP53 MET EGFR CD274
78 parotid gland cancer 10.2 TP53 CAGE1
79 suppressor of tumorigenicity 3 10.2 TP53 CDKN2A BCL2
80 supraglottis neoplasm 10.2 CDKN2A CAGE1
81 short syndrome 10.2 TP53 EGFR AKT1
82 localized osteosarcoma 10.2 TP53 CD274 AKT1
83 mixed cell type cancer 10.2 TP53 EGFR CDKN2A CDH1
84 dedifferentiated liposarcoma 10.2 TP53 CDKN2A CD274
85 lymphoepithelioma-like carcinoma 10.2 TP53 EGFR CDKN2A CD274
86 anal squamous cell carcinoma 10.2 TP53 EGFR CDKN2A CD274
87 breast fibroadenoma 10.2 TP53 NME1 NGFR EGFR
88 vaginal cancer 10.2 TP53 EGFR CDKN2A CD274
89 lung large cell carcinoma 10.2 TP53 NME1 EGFR CD274
90 colorectal adenoma 10.2 TP53 MIR143 EGFR CDH1
91 vulva squamous cell carcinoma 10.2 TP53 EGFR CDKN2A CD274
92 biliary tract cancer 10.2 TP53 MIR143 MET EGFR
93 cholecystitis 10.2 TP53 EGFR CDKN2A CDH1
94 vulvar disease 10.2 TP53 EGFR CDKN2A CD274
95 peritoneum cancer 10.2 TP53 EGFR CDKN2A CD274
96 borst-jadassohn intraepidermal carcinoma 10.2 TP53 CDKN2A BCL2
97 penile disease 10.2 TP53 EGFR CDKN2A CD274
98 vulva cancer 10.2 TP53 EGFR CDKN2A CD274
99 small intestine cancer 10.2 TP53 EGFR CDKN2A CD274
100 osteonecrosis 10.2
101 cartilage disease 10.2
102 cardiovascular organ benign neoplasm 10.2 TP53 MIR143 AKT1
103 pleural disease 10.2 TP53 EGFR CDKN2A CD274
104 cervical squamous cell carcinoma 10.2 TP53 EGFR CDKN2A CDH1
105 malignant spindle cell melanoma 10.1 TP53 NGFR CDKN2A CD274
106 plexiform neurofibroma 10.1 TP53 EGFR CDKN2A AKT1
107 lung adenoma 10.1 TP53 EGFR CDKN2A AKT1
108 cystadenocarcinoma 10.1 TP53 BCL2 AKT1
109 endometrial adenocarcinoma 10.1 TP53 EGFR CDKN2A AKT1
110 exanthem 10.1 EGFR CD274 AKT1
111 bone osteosarcoma 10.1 TP53 CDKN2A AKT1
112 ovarian serous cystadenocarcinoma 10.1 TP53 EGFR CDKN2A AKT1
113 thyroid gland follicular carcinoma 10.1 TP53 CDH1 AKT1
114 low grade glioma 10.1 TP53 EGFR CDKN2A AKT1
115 central nervous system benign neoplasm 10.1 TP53 EGFR CDKN2A AKT1
116 infratentorial cancer 10.1 TP53 EGFR CDKN2A AKT1
117 larynx squamous papilloma 10.1 TP53 CDKN2A
118 rectal benign neoplasm 10.1 TP53 MIR143 EGFR CAGE1
119 breast lobular carcinoma 10.1 TP53 EGFR CDH1 AKT1
120 serous cystadenocarcinoma 10.1 TP53 CDKN2A CDH1 AKT1
121 esophagus adenocarcinoma 10.1 TP53 MIR143 EGFR CDKN2A CDH1
122 hypoparathyroidism 10.1
123 melanoma, cutaneous malignant 1 10.1 TP53 EGFR CDKN2A AKT1
124 cowden syndrome 10.1 TP53 EGFR CDKN2A AKT1
125 rhabdomyosarcoma 2 10.1
126 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.1
127 leukemia, acute lymphoblastic 3 10.1
128 aspiration pneumonia 10.1
129 b-lymphoblastic leukemia/lymphoma 10.1
130 severe combined immunodeficiency 10.1
131 malignant peripheral nerve sheath tumor 10.1 TP53 NGFR MET EGFR CDKN2A
132 actinic keratosis 10.1 TP53 EGFR CDKN2A BCL2
133 keratosis 10.1 TP53 EGFR CDKN2A BCL2
134 inherited cancer-predisposing syndrome 10.1 TP53 MET EGFR CDKN2A CDH1
135 retinitis pigmentosa 11 10.1 TP53 EGFR CDKN2A AKT1
136 bap1 tumor predisposition syndrome 10.1 TP53 MET EGFR CDKN2A CDH1
137 female breast cancer 10.1 TP53 EGFR CDKN2A BCL2
138 intrahepatic cholangiocarcinoma 10.1 TP53 EGFR CD274 AKT1
139 uterine carcinosarcoma 10.1 TP53 EGFR CD274 AKT1
140 rectum cancer 10.1 TP53 MIR143 EGFR CAGE1
141 bladder urothelial carcinoma 10.1 TP53 CDKN2A CDH1 AKT1
142 sensory system disease 10.1 TP53 MIR143 CDKN2A AKT1
143 tongue squamous cell carcinoma 10.1 TP53 MIR143 CDH1 AKT1
144 myoma 10.1 TP53 EGFR BCL2
145 ovary epithelial cancer 10.1 TP53 MIR143 CDH1 AKT1
146 endometrial hyperplasia 10.1 TP53 CDKN2A BCL2
147 skin papilloma 10.1 TP53 STAT3 EGFR AKT1
148 macroglobulinemia 10.1 TP53 BCL2 AKT1
149 penile cancer 10.1 TP53 EGFR CDKN2A CDH1 CD274
150 adrenal cortical carcinoma 10.1 TP53 EGFR CD274 AKT1
151 cell type benign neoplasm 10.0 TP53 MIR143 EGFR CDKN2A AKT1
152 oligodendroglioma 10.0 TP53 EGFR CDKN2A BCL2
153 skeletal muscle cancer 10.0 TP53 BCL2 AKT1
154 brain glioblastoma multiforme 10.0 TP53 EGFR BCL2 AKT1
155 leiomyosarcoma 10.0 TP53 CDKN2A CD274 BCL2
156 skin squamous cell carcinoma 10.0 TP53 EGFR CDKN2A CDH1 AKT1
157 gastroesophageal adenocarcinoma 10.0 TP53 MET EGFR CD274 AKT1
158 tonsil cancer 10.0 TP53 EGFR CDKN2A CDH1 AKT1
159 breast carcinoma in situ 10.0 TP53 EGFR CDKN2A CDH1 AKT1
160 ductal carcinoma in situ 10.0 TP53 EGFR CDKN2A CDH1 AKT1
161 liposarcoma 10.0 TP53 CDKN2A CD274 BCL2
162 uterine benign neoplasm 10.0 TP53 CDKN2A BCL2 AKT1
163 reproductive organ benign neoplasm 10.0 TP53 CDKN2A BCL2 AKT1
164 ovary adenocarcinoma 10.0 TP53 EGFR CDKN2A CDH1 AKT1
165 endocervical carcinoma 10.0 TP53 EGFR CDKN2A CD274 AKT1
166 skin melanoma 10.0 TP53 NME1 CDKN2A CD274 AKT1
167 camptodactyly-arthropathy-coxa vara-pericarditis syndrome 10.0
168 vasculitis 10.0
169 47 xxx syndrome 10.0
170 plummer vinson syndrome 10.0
171 pleural cancer 10.0 TP53 EGFR CDKN2A CD274 AKT1
172 neurofibromatosis, type i 10.0 TP53 NGFR EGFR CDKN2A AKT1
173 bone squamous cell carcinoma 10.0 TP53 STAT3 EGFR CDKN2A CD274
174 human papillomavirus infectious disease 10.0 TP53 EGFR CDKN2A CD274 AKT1
175 amelogenesis imperfecta, type ig 10.0 TP53 EGFR BCL2 AKT1
176 amelogenesis imperfecta 10.0 TP53 EGFR BCL2 AKT1
177 mature b-cell neoplasm 10.0 TP53 CDKN2A BCL2 AKT1
178 neurodegeneration with brain iron accumulation 2a 10.0
179 supraglottis cancer 10.0
180 factor vii deficiency 10.0
181 fanconi anemia, complementation group a 10.0
182 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
183 stroke, ischemic 10.0
184 deficiency anemia 10.0
185 hypothyroidism 10.0
186 inappropriate adh syndrome 10.0
187 spondylitis 10.0
188 49, xxxxy syndrome 10.0
189 49,xxxxx syndrome 10.0
190 49,xyyyy syndrome 10.0
191 kidney cancer 10.0 TP53 MIR489 MET EGFR CDKN2A CD274
192 basal cell nevus syndrome 10.0 TP53 BCL2 AKT1
193 bone sarcoma 10.0 TP53 MIR143 BCL2 AKT1
194 gliosarcoma 10.0 TP53 EGFR CDKN2A CD274 AKT1
195 retinal cancer 10.0 TP53 CDKN2A BCL2 AKT1
196 peripheral t-cell lymphoma 10.0 TP53 STAT3 NME1 BCL2
197 anus disease 10.0 TP53 EGFR CDKN2A CD274 CAGE1
198 rectal disease 10.0 TP53 EGFR CDKN2A CD274 CAGE1
199 uterine body mixed cancer 10.0 TP53 EGFR CDH1 CD274 AKT1
200 rectum adenocarcinoma 10.0 TP53 MIR143 EGFR CD274 CAGE1
201 autonomic nervous system neoplasm 10.0 TP53 EGFR BCL2 AKT1
202 rabies 10.0 NGFR CD274 BCL2
203 testicular disease 10.0 TP53 CD274 BCL2 AKT1
204 cheilitis 10.0 TP53 STAT3 CD274 BCL2
205 li-fraumeni syndrome 10.0 TP53 EGFR CDKN2A CDH1 BCL2
206 transitional cell carcinoma 10.0 TP53 NME1 EGFR CDH1 BCL2
207 toxic encephalopathy 10.0 TP53 BCL2 AKT1
208 mature t-cell and nk-cell lymphoma 10.0 TP53 STAT3 CD274 BCL2
209 conjunctival squamous cell carcinoma 10.0 TP53 CDKN2A
210 respiratory system benign neoplasm 10.0 TP53 EGFR CDKN2A BCL2 AKT1
211 rasopathy 10.0 TP53 STAT3 EGFR CDKN2A AKT1
212 sezary's disease 10.0 TP53 STAT3 CD274 BCL2
213 blood platelet disease 9.9 TP53 CD274 BCL2 AKT1
214 muscle cancer 9.9 TP53 EGFR CDKN2A BCL2 AKT1
215 malignant exocrine pancreas neoplasm 9.9 TP53 MIR143 EGFR CDKN2A CDH1 AKT1
216 small cell cancer of the lung 9.9 TP53 EGFR CDKN2A BCL2 AKT1
217 peripheral nervous system neoplasm 9.9 TP53 MIR143 EGFR BCL2 AKT1
218 testicular cancer 9.9 TP53 CD274 BCL2 AKT1
219 myelofibrosis 9.9 TP53 STAT3 CDKN2A CD274
220 brain cancer 9.9 TP53 STAT3 MIR143 EGFR AKT1
221 lung squamous cell carcinoma 9.9 TP53 MIR143 EGFR CDKN2A CD274 AKT1
222 integumentary system disease 9.9 TP53 STAT3 EGFR CD274 AKT1
223 malignant astrocytoma 9.9 TP53 MIR143 EGFR AKT1
224 bone marrow cancer 9.9 TP53 STAT3 BCL2 AKT1
225 breast ductal carcinoma 9.9 TP53 NME1 MET EGFR CDH1 BCL2
226 ovarian cystadenocarcinoma 9.9 TP53 EGFR CDKN2A CDH1 CD274 AKT1
227 uterine corpus cancer 9.9 TP53 EGFR CDKN2A CDH1 CD274 AKT1
228 bile duct adenocarcinoma 9.9 TP53 MIR143 EGFR CDH1 CD274 AKT1
229 thymus cancer 9.9 TP53 EGFR CD274 BCL2 AKT1
230 suppression of tumorigenicity 12 9.9 TP53 EGFR CDKN2A CDH1 CD274 AKT1
231 chromophobe renal cell carcinoma 9.9 TP53 SNHG7 EGFR CDH1 CD274 AKT1
232 lynch syndrome 9.9 TP53 EGFR CDKN2A CDH1 CD274 AKT1
233 colon adenoma 9.9 TP53 STAT3 MIR143 EGFR CDH1 AKT1
234 autoimmune disease 9.9
235 tobacco addiction 9.9
236 mycosis fungoides 9.9
237 ataxia with vitamin e deficiency 9.9
238 microvascular complications of diabetes 1 9.9
239 spastic paraplegia, ataxia, and mental retardation 9.9
240 neutrophilic dermatosis, acute febrile 9.9
241 microvascular complications of diabetes 2 9.9
242 microvascular complications of diabetes 3 9.9
243 microvascular complications of diabetes 4 9.9
244 microvascular complications of diabetes 5 9.9
245 microvascular complications of diabetes 6 9.9
246 microvascular complications of diabetes 7 9.9
247 hypoalphalipoproteinemia, primary, 2 9.9
248 angiosarcoma 9.9
249 rapidly involuting congenital hemangioma 9.9
250 multicentric castleman disease 9.9
251 castleman disease 9.9
252 laryngostenosis 9.9
253 fungal infectious disease 9.9
254 lymphadenitis 9.9
255 cystadenoma 9.9
256 acute kidney failure 9.9
257 neurilemmoma 9.9
258 mammary paget's disease 9.9
259 esophagus squamous cell carcinoma 9.9
260 pyoderma 9.9
261 pleomorphic adenoma 9.9
262 cerebrovascular disease 9.9
263 pyoderma gangrenosum 9.9
264 amyloidosis 9.9
265 polyarteritis nodosa 9.9
266 catastrophic antiphospholipid syndrome 9.9
267 cryopyrin-associated periodic syndrome 9.9
268 cytokine deficiency 9.9
269 warthin tumor 9.9
270 tremor 9.9
271 estrogen-receptor positive breast cancer 9.9 TP53 STAT3 EGFR BCL2 AKT1
272 pneumothorax, primary spontaneous 9.9
273 acetyl-coa acetyltransferase-2 deficiency 9.9
274 brugada syndrome 9.9
275 mucositis 9.9
276 pneumothorax 9.9
277 pericarditis 9.9
278 laryngeal cleft 9.9
279 alcohol dependence 9.9
280 apnea, obstructive sleep 9.9
281 atherosclerosis susceptibility 9.9
282 gastroesophageal reflux 9.9
283 thrombophilia due to thrombin defect 9.9
284 down syndrome 9.9
285 leukoencephalopathy, hereditary diffuse, with spheroids 1 9.9
286 hypoascorbemia 9.9
287 laurence-moon syndrome 9.9
288 proteasome-associated autoinflammatory syndrome 1 9.9
289 ocular motor apraxia 9.9
290 helicobacter pylori infection 9.9
291 premature ovarian failure 7 9.9
292 macs syndrome 9.9
293 secondary progressive multiple sclerosis 9.9
294 sleep apnea 9.9
295 colitis 9.9
296 thrombosis 9.9
297 combined immunodeficiency 9.9
298 sensorineural hearing loss 9.9
299 osteomyelitis 9.9
300 keratomalacia 9.9
301 epidural abscess 9.9
302 pericardial effusion 9.9
303 esophagitis 9.9
304 bile reflux 9.9
305 neutropenia 9.9
306 nephrocalcinosis 9.9
307 quadriplegia 9.9
308 carotid stenosis 9.9
309 gout 9.9
310 alcohol use disorder 9.9
311 duodenal ulcer 9.9
312 transient cerebral ischemia 9.9
313 pharyngitis 9.9
314 lateral sclerosis 9.9
315 gastric antral vascular ectasia 9.9
316 lipid metabolism disorder 9.9
317 carotid artery disease 9.9
318 pleural empyema 9.9
319 liver disease 9.9
320 liver cirrhosis 9.9
321 pneumonia 9.9
322 esophageal disease 9.9
323 acquired immunodeficiency syndrome 9.9
324 lymphatic system disease 9.9
325 mediastinitis 9.9
326 ileus 9.9
327 oral cavity cancer 9.9
328 48,xxxy syndrome 9.9
329 48,xxyy syndrome 9.9
330 48,xyyy 9.9
331 boerhaave syndrome 9.9
332 klebsiella infection 9.9
333 sudden sensorineural hearing loss 9.9
334 syndrome of inappropriate antidiuretic hormone 9.9
335 swallowing disorders 9.9
336 syncope 9.9
337 acute sensory ataxic neuropathy 9.9
338 cardiogenic shock 9.9
339 thyroid carcinoma 9.9
340 myocarditis 9.9 STAT3 CD274 BCL2 AKT1
341 brain glioma 9.9 TP53 STAT3 EGFR CDKN2A CD274 AKT1
342 follicular lymphoma 9.8 TP53 STAT3 CDKN2A BCL2 AKT1
343 burkitt lymphoma 9.8 TP53 STAT3 NME1 MIR143 CDKN2A BCL2
344 anus cancer 9.8 TP53 EGFR CDKN2A CD274 CAGE1 AKT1
345 bone cancer 9.8 TP53 STAT3 MIR143 EGFR CDKN2A BCL2
346 gastric adenocarcinoma 9.8 TP53 MET CDKN2A CDH1 BCL2 AKT1
347 thyroid gland anaplastic carcinoma 9.8 TP53 MET EGFR CDH1 BCL2 AKT1
348 pre-malignant neoplasm 9.8 TP53 EGFR CDKN2A CDH1 BCL2 AKT1
349 gallbladder disease 9.8 TP53 MIR143 EGFR CDH1 BCL2 AKT1
350 osteogenic sarcoma 9.8 TP53 MET CDKN2A AKT1
351 renal cell carcinoma, papillary, 1 9.8 TP53 MET EGFR CDKN2A CDH1 CD274
352 chordoma 9.8 TP53 MET EGFR CDKN2A CDH1 CD274
353 hemangioma 9.8 TP53 EGFR CDKN2A CDH1 BCL2 AKT1
354 adenoid cystic carcinoma 9.8 TP53 EGFR CDKN2A CDH1 BCL2 AKT1
355 thymoma 9.8 TP53 EGFR CDKN2A CD274 BCL2 AKT1
356 meningioma, familial 9.8 TP53 EGFR CDKN2A CDH1 BCL2 AKT1
357 malignant ovarian surface epithelial-stromal neoplasm 9.8 TP53 EGFR CDH1 CD274 BCL2 AKT1
358 common variable immunodeficiency 9.8 TP53 STAT3 BCL2 AKT1
359 pheochromocytoma 9.8 STAT3 NME1 NGFR CDKN2A CDH1 BCL2
360 estrogen-receptor negative breast cancer 9.8 TP53 STAT3 EGFR CDH1 BCL2 AKT1
361 teratoma 9.8 TP53 STAT3 CDKN2A CDH1 BCL2 AKT1
362 thyroid gland cancer 9.8 TP53 NME1 MET EGFR CDH1 BCL2
363 leukemia, chronic myeloid 9.7 TP53 STAT3 NME1 EGFR BCL2 AKT1
364 tongue disease 9.7 TP53 MIR143 EGFR CDKN2A CDH1 BCL2
365 tongue carcinoma 9.7 TP53 MIR143 EGFR CDKN2A CDH1 BCL2
366 thymus gland disease 9.7 TP53 STAT3 EGFR CD274 BCL2 AKT1
367 pancreatic ductal carcinoma 9.7 TP53 STAT3 EGFR CDKN2A CDH1 CD274
368 leukocyte disease 9.7 TP53 STAT3 EGFR CD274 BCL2 AKT1
369 interstitial lung disease 2 9.7 TP53 STAT3 EGFR CDH1 BCL2 AKT1
370 myeloma, multiple 9.7 TP53 STAT3 MET BCL2 AKT1
371 colorectal adenocarcinoma 9.7 TP53 MIR143 EGFR CDH1 CD274 BCL2
372 lymphoma, non-hodgkin, familial 9.7 TP53 STAT3 MIR143 CD274 BCL2 AKT1
373 pancreatic adenocarcinoma 9.7 TP53 STAT3 MET EGFR CDKN2A BCL2
374 skin carcinoma 9.7 TP53 EGFR CDKN2A CDH1 CD274 BCL2
375 high grade glioma 9.7 TP53 STAT3 MET EGFR CDKN2A BCL2
376 wilms tumor 1 9.7 TP53 EGFR CDKN2A CDH1 CD274 BCL2
377 cervical cancer 9.7 TP53 STAT3 NME1 MIR143 CDKN2A BCL2
378 gastrointestinal system benign neoplasm 9.7 TP53 STAT3 MIR143 EGFR CDH1 BCL2
379 lymphangioma 9.7 TP53 STAT3 MIR143 EGFR CDH1 BCL2
380 cholangiocarcinoma 9.6 TP53 STAT3 MET EGFR CDKN2A CDH1
381 basal cell carcinoma 9.6 TP53 STAT3 EGFR CDKN2A CDH1 BCL2
382 mantle cell lymphoma 9.6 TP53 STAT3 EGFR CDKN2A CD274 BCL2
383 lymphoma 9.6 TP53 STAT3 EGFR CDKN2A CD274 BCL2
384 myocardial infarction 9.6 TP53 STAT3 MIR143 CDKN2A BCL2 ALDH2
385 hypertension, essential 9.6 TP53 STAT3 MIR143 EGFR BCL2 ALDH2
386 hepatoblastoma 9.6 TP53 STAT3 MET EGFR CDKN2A CDH1
387 intestinal benign neoplasm 9.6 TP53 STAT3 MIR143 EGFR CDKN2A CDH1
388 colonic benign neoplasm 9.6 TP53 STAT3 MIR143 EGFR CDKN2A CDH1
389 gastrointestinal stromal tumor 9.6 TP53 STAT3 MET EGFR CDKN2A CD274
390 rhabdomyosarcoma 9.5 TP53 STAT3 MET EGFR CDKN2A CD274
391 leukemia, chronic lymphocytic 9.5 TP53 STAT3 MIR143 EGFR CDKN2A CD274
392 bile duct cancer 9.5 TP53 MIR143 MET EGFR CDKN2A CDH1
393 cervix carcinoma 9.5 TP53 STAT3 EGFR CDKN2A CDH1 CD274
394 malignant pleural mesothelioma 9.5 TP53 SNHG7 MET EGFR CDKN2A CDH1
395 breast adenocarcinoma 9.5 TP53 STAT3 EGFR CDKN2A CDH1 CD274
396 leukemia, acute myeloid 9.5 TP53 STAT3 EGFR CDKN2A CDH1 CD274
397 cystic fibrosis 9.5 TP53 STAT3 EGFR CDH1 BCL2 AKT1
398 glioblastoma 9.5 TP53 STAT3 SNHG7 MET EGFR CDKN2A
399 endometrial cancer 9.5 TP53 STAT3 NME1 MET EGFR CDKN2A
400 retinitis pigmentosa 9.5 TP53 STAT3 NGFR EGFR CDKN2A CDH1
401 adenocarcinoma 9.4 TP53 STAT3 MET EGFR CDKN2A CDH1
402 medulloblastoma 9.4 TP53 STAT3 NGFR MET EGFR CDKN2A
403 eye disease 9.4 TP53 STAT3 MIR143 EGFR CDKN2A CDH1
404 connective tissue disease 9.4 TP53 STAT3 MIR143 EGFR CDKN2A CDH1
405 bladder cancer 9.4 TP53 STAT3 NME1 MIR143 MET EGFR
406 skin disease 9.4 TP53 STAT3 NGFR EGFR CDKN2A CDH1
407 gallbladder cancer 9.4 TP53 STAT3 NME1 MIR143 EGFR CDKN2A
408 renal cell carcinoma, nonpapillary 9.3 TP53 STAT3 MIR143 MET EGFR CDKN2A
409 melanoma 9.3 TP53 STAT3 NME1 NGFR MET CDKN2A
410 melanoma, uveal 9.3 TP53 NME1 NGFR MIR143 MET EGFR
411 peripheral nervous system disease 9.3 TP53 STAT3 NGFR MIR143 EGFR CDKN2A
412 neuroblastoma 9.3 TP53 STAT3 NME1 NGFR EGFR CDKN2A
413 pancreatic cancer 9.3 TP53 STAT3 NGFR MIR143 MET EGFR
414 ovarian cancer 9.3 TP53 STAT3 NME1 MET EGFR CDKN2A
415 hepatocellular carcinoma 9.2 TP53 STAT3 NME1 MIR143 MET EGFR
416 nervous system disease 9.2 TP53 STAT3 NGFR MIR143 MET EGFR
417 prostate cancer 9.2 TP53 STAT3 NME1 NGFR MIR143 MET
418 breast cancer 9.0 TP53 STAT3 SNHG7 NME1 NGFR MIR143

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN): (showing 1, show less)


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer

Symptoms & Phenotypes for Hypopharynx Cancer

GenomeRNAi Phenotypes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

25 (showing 59, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 10.1 MET
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.1 CD274
3 Increased shRNA abundance (Z-score > 2) GR00366-A-106 10.1 BCL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.1 MET
5 Increased shRNA abundance (Z-score > 2) GR00366-A-119 10.1 MET NME1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.1 NME1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.1 EGFR
8 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.1 STAT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-134 10.1 BCL2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.1 BCL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.1 BCL2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.1 ALDH2 CD274 STAT3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.1 ALDH2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.1 MET
15 Increased shRNA abundance (Z-score > 2) GR00366-A-187 10.1 CD274
16 Increased shRNA abundance (Z-score > 2) GR00366-A-191 10.1 MET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.1 BCL2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.1 BCL2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-201 10.1 MET
20 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.1 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.1 BCL2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-212 10.1 STAT3
23 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.1 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.1 EGFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.1 NME1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.1 CD274
27 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.1 CD274
28 Increased shRNA abundance (Z-score > 2) GR00366-A-33 10.1 ALDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.1 ALDH2
30 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.1 BCL2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-38 10.1 MET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-4 10.1 MET
33 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.1 ALDH2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.1 EGFR
35 Increased shRNA abundance (Z-score > 2) GR00366-A-53 10.1 NME1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.1 NME1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-59 10.1 BCL2
38 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.1 AKT1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.1 MET
40 Increased shRNA abundance (Z-score > 2) GR00366-A-68 10.1 BCL2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.1 AKT1 BCL2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-75 10.1 NME1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.1 BCL2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.1 MET
45 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.1 ALDH2
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.1 AKT1 ALDH2 CD274 EGFR MET NME1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.1 ALDH2
48 Increased shRNA abundance (Z-score > 2) GR00366-A-88 10.1 BCL2
49 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.1 EGFR
50 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.1 BCL2
51 Decreased viability GR00055-A-1 9.93 EGFR
52 Decreased viability GR00055-A-2 9.93 EGFR
53 Decreased viability GR00221-A-1 9.93 AKT1 CDH1 CDKN2A EGFR NME1
54 Decreased viability GR00221-A-2 9.93 AKT1 NME1
55 Decreased viability GR00221-A-3 9.93 AKT1 CDKN2A
56 Decreased viability GR00221-A-4 9.93 AKT1 CDKN2A EGFR
57 Decreased viability GR00249-S 9.93 AKT1 NME1
58 Decreased viability GR00301-A 9.93 CDH1
59 Decreased viability GR00402-S-2 9.93 CDH1 NME1

MGI Mouse Phenotypes related to Hypopharynx Cancer:

45 (showing 7, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.1 AKT1 ALDH2 BCL2 CDH1 CDKN2A EGFR
2 muscle MP:0005369 10.02 AKT1 ALDH2 BCL2 CDKN2A EGFR MET
3 liver/biliary system MP:0005370 9.97 AKT1 ALDH2 CDKN2A EGFR MET NGFR
4 endocrine/exocrine gland MP:0005379 9.96 AKT1 ALDH2 BCL2 CDH1 CDKN2A EGFR
5 digestive/alimentary MP:0005381 9.76 BCL2 CDH1 CDKN2A EGFR MET NGFR
6 cardiovascular system MP:0005385 9.7 AKT1 ALDH2 BCL2 CDH1 CDKN2A EGFR
7 integument MP:0010771 9.36 AKT1 ALDH2 BCL2 CD274 CDH1 CDKN2A

Drugs & Therapeutics for Hypopharynx Cancer

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 100, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
2
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Fluorouracil Approved Phase 3 51-21-8 3385
5
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
6
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
7
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
8
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 5702198 441203
9
Cetuximab Approved Phase 2, Phase 3 205923-56-4
10
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
11
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
14 Nicotinic Acids Phase 3
15 Lipid Regulating Agents Phase 3
16 Micronutrients Phase 3
17 Folate Phase 3
18 Vitamins Phase 3
19 Trace Elements Phase 3
20 Vitamin B9 Phase 3
21 Vitamin B3 Phase 3
22 Vitamin B Complex Phase 3
23 Hypolipidemic Agents Phase 3
24 Vasodilator Agents Phase 3
25 Tubulin Modulators Phase 3
26 Antimitotic Agents Phase 3
27 Albumin-Bound Paclitaxel Phase 3
28 Mitogens Phase 2, Phase 3
29 Endothelial Growth Factors Phase 2, Phase 3
30 Immunosuppressive Agents Phase 3
31 Angiogenesis Inhibitors Phase 2, Phase 3
32 Antineoplastic Agents, Immunological Phase 2, Phase 3
33 Antibodies Phase 2, Phase 3
34 Immunoglobulins Phase 2, Phase 3
35 Immunologic Factors Phase 2, Phase 3
36 Antibodies, Monoclonal Phase 2, Phase 3
37 Immunoglobulins, Intravenous Phase 2, Phase 3
38 Immunoglobulin G Phase 2, Phase 3
39 Pharmaceutical Solutions Phase 3
40 Raspberry Approved Phase 1, Phase 2
41
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
42
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
43
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
44
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
45
Nivolumab Approved Phase 2 946414-94-4
46
Promethazine Approved, Investigational Phase 2 60-87-7 4927
47
Histamine Approved, Investigational Phase 2 51-45-6 774
48
Doxepin Approved, Investigational Phase 2 1668-19-5 667468 667477
49
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
50
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
51
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
52
Nimotuzumab Investigational Phase 2 780758-10-3
53
Pyrazole Experimental Phase 2 288-13-1
54 N-Methylaspartate Phase 1, Phase 2
55
Arginyl-glycyl-aspartic acid Phase 1, Phase 2 3328704
56 Radiopharmaceuticals Phase 1, Phase 2
57 Fluorodeoxyglucose F18 Phase 1, Phase 2
58 Fluorides Phase 1, Phase 2
59 Taxane Phase 2 108169
60 Antimetabolites Phase 2
61 Carbonic Anhydrase Inhibitors Phase 2
62 Cyclooxygenase Inhibitors Phase 2
63 Cyclooxygenase 2 Inhibitors Phase 2
64
Benzenesulfonamide Phase 2 7370
65 Antirheumatic Agents Phase 2
66 Anti-Inflammatory Agents, Non-Steroidal Phase 2
67 Analgesics, Non-Narcotic Phase 2
68 Anti-Inflammatory Agents Phase 2
69 Analgesics Phase 2
70
Sodium thiosulfate Phase 2
71 Chelating Agents Phase 2
72 Antidotes Phase 2
73 Antitubercular Agents Phase 2
74 Protective Agents Phase 2
75 Anti-Infective Agents Phase 2
76 Antioxidants Phase 2
77 Anti-Bacterial Agents Phase 2
78 Immune Checkpoint Inhibitors Phase 2
79 Neurotransmitter Agents Phase 2
80 Antidepressive Agents, Tricyclic Phase 2
81 Antidepressive Agents Phase 2
82 Psychotropic Drugs Phase 2
83
Histamine phosphate Phase 2 51-74-1 134614
84 Histamine Antagonists Phase 2
85 Hypnotics and Sedatives Phase 2
86
Arginine Investigational, Nutraceutical Phase 1, Phase 2 74-79-3 6322
87
Adenosine Approved, Investigational Phase 1 58-61-7 60961
88
Nedisertib Investigational Phase 1 1637542-33-6 86292849
89
Motexafin gadolinium Investigational Phase 1 246252-06-2
90 Protein Kinase Inhibitors Phase 1
91 Dermatologic Agents Phase 1
92 Photosensitizing Agents Phase 1
93
Silicon Approved, Investigational 7440-21-3 4082203
94
Metoclopramide Approved, Investigational 364-62-5 4168
95
Ethanol Approved 64-17-5 702
96
Dopamine Approved 62-31-7, 51-61-6 681
97 Gastrointestinal Agents
98 Antiemetics
99 Dopamine Antagonists
100 Dopamine Agents

Interventional clinical trials:

(showing 70, show less)
# Name Status NCT ID Phase Drugs
1 Randomized Study Comparing Induction Chemotherapy With Docetaxel, Cisplatin, 5FU Versus Cisplatin, 5 FU in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL;Cisplatin;5-Fluoro-3-Pyridinecarboxylic Acid
2 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
3 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
4 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
5 A Randomized Phase III Comparing Sequential Therapy With Induction Chemotherapy/Chemoradiation To Cisplatinum-Based Chemoradiotherapy in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT04502641 Phase 3 Docetaxel;5-fluorouracil;Cisplatin;Platinum
6 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
7 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Active, not recruiting NCT03258554 Phase 2, Phase 3
8 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
9 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
10 Multi-Institutional Phase II Study of Weekly Docetaxel and Concurrent Radiotherapy for Laryngeal and Hypopharyngeal Cancer in the Group of Elderly and/or Patients With Medical Illness Completed NCT00243113 Phase 2 docetaxel
11 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
12 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
13 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
14 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
15 A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy Completed NCT03096808 Phase 2
16 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
17 Induction Chemotherapy Combined With Camrelizumab Followed by Chemoradiotherapy in Locoregionally Advanced Hypopharyngeal Cancer Recruiting NCT04539600 Phase 2 Camrelizumab
18 New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT03558035 Phase 2 Induction CT+ CRT group
19 Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma Recruiting NCT05420597 Phase 2 Toripalimab
20 Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma Recruiting NCT04995120 Phase 2 chemotherapy TP regimen combined with Toripalimab
21 Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE) Recruiting NCT02757222 Phase 1, Phase 2
22 RESILIENCE: Effect of Comprehensive Celecoxib Through Treatment for Advanced-Stage Head and Neck Cancer: A Randomized, Double-Blinded, Placebo-Controlled Trial Recruiting NCT04162873 Phase 2 Celecoxib
23 A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting NCT04862650 Phase 2 Carboplatin;Paclitaxel
24 A Phase 2 Study of Ipatasertib in Combination With Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Recruiting NCT05172258 Phase 2 Ipatasertib
25 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
26 A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT04156698 Phase 2 Docetaxel;Cisplatin;Capecitabine;Camrelizumab
27 Hypofractionated Proton Therapy for the Treatment of Head and Neck Cancer, The HEADLIGHT Study" Recruiting NCT05075980 Phase 2 Cisplatin
28 Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Active, not recruiting NCT03894891 Phase 2 Nivolumab;Cisplatin;Docetaxel
29 An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Active, not recruiting NCT03082534 Phase 2 Pembrolizumab, Cetuximab
30 A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin Active, not recruiting NCT04541355 Phase 2 Cisplatin;Sodium Thiosulfate
31 A Single-arm Study Evaluating Efficacy and Safety of Toripalimab Combined With Docetaxel and Cisplatin as Induced Chemotherapy in the Treatment of Localized Hypopharyngeal Squamous Cell Carcinoma Not yet recruiting NCT04296747 Phase 2 induction chemotherapy
32 Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study Not yet recruiting NCT04624308 Phase 2 Toripalimab
33 Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study Not yet recruiting NCT05136196 Phase 2 Cabozantinib S-malate
34 A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy Terminated NCT02062632 Phase 2 Doxepin Hydrochloride
35 A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT02113878 Phase 1 BKM120;Cisplatin
36 Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer Recruiting NCT05172245 Phase 1 Cisplatin;Ipatasertib
37 Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Recruiting NCT04533750 Phase 1 Peposertib
38 Proton Image-Guided Radiation Assignment for Therapeutic Escalation Via Selection of Locally Advanced Head and Neck Cancer Patients [PIRATES] Recruiting NCT04870840 Phase 1
39 Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell Carcinoma Recruiting NCT04576091 Phase 1 Elimusertib
40 Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02586207 Phase 1 pembrolizumab (MK-3475);Cisplatin
41 A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) Not yet recruiting NCT04892875 Phase 1 Zimberelimab;Etrumadenant;Cisplatin
42 Phase I Trial of Motexafin Gadolinium and Chemoradiation in Locally Advanced, Squamous Cell Carcinoma of the Head and Neck Terminated NCT00080028 Phase 1 Motexafin Gadolinium Injection
43 A Pilot Study Assessing Transoral Robotic Surgery (TORS) for Oral and Laryngopharyngeal Benign and Malignant Lesions Using the Da Vinci Robotic Surgical System Unknown status NCT01473784
44 The Role of Stromal Cell-Derived Factor-1 (SDF-1)/CXC Chemokine Receptor 4 (CXCR4) in Metastasis of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00174096
45 The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Unknown status NCT00173381
46 The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Unknown status NCT00302562
47 A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients Unknown status NCT03039465
48 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
49 Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer Completed NCT03132727
50 Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial Completed NCT03934294 Metoclopramide 10mg
51 Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery Completed NCT00473564
52 A Multicenter OUS Post-Market Clinical Follow-Up of the Medrobotics Flex® Robotic System Used for Accessing and Visualizing the Oropharynx, Hypopharynx, and Larynx During Transoral Procedures Completed NCT02262247
53 A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery: A Prospective, Single Center, Multispecialty Study Completed NCT03010813
54 Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA Completed NCT00534729 Weekly Carboplatin & Taxol w/concurrent RT
55 Pharmacogenetic and Pharmacokinetic Aspects of the Response to Chemotherapy Induction Using Docetaxel, Cisplatin and 5-Fluorouracile (TPF)in ORL Cancers Completed NCT01104714
56 Determination of Diagnostic Benefit of Enhanced Contact Endoscopy (ECE) in Pre-histological Diagnosis of Laryngeal and Hypopharyngeal Mucosal Lesions Recruiting NCT04777474
57 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
58 Cell-free Tumor DNAand HPV-DNA in Blood Samples From Newly Diagnosed Patients With Head and Neck Cancer Recruiting NCT03942380
59 Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy Recruiting NCT05337631
60 Modeling Adherence to Preventive Swallowing Exercises in Head and Neck Cancer Recruiting NCT03010150
61 "CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial" Recruiting NCT01365169
62 Phase III Study Assessing the "Best of" Radiotherapy Compared to the "Best of" Surgery (Trans-oral Surgery (TOS)) in Patients With T1-T2, N0-N1 Oropharyngeal, Supraglottic Carcinoma and With T1, N0 Hypopharyngeal Carcinoma Recruiting NCT02984410
63 A Pilot Study to Assess Feasibility of a Clinically Significant Increase in Physical Activity in Patients With Head and Neck Cancer Undergoing Active Treatment Recruiting NCT04788264
64 The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma: A Multi-center Randomized Controlled Prospective Study Recruiting NCT05494190 Docetaxel;Cisplatin;Capecitabine
65 Immune Biomarker Study for Head and Neck Cancer Not yet recruiting NCT05375266
66 Neck Dissection Versus Radiotherapy for Cervical Lymph Node Metastasis in Advanced Hypopharyngeal Carcinoma With Poor Response to Induction Chemotherapy : A Randomized Controlled Prospective Study Not yet recruiting NCT03367884
67 Effects of a Pneumatic Compression Device in Post-Chemoradiation Head and Neck Cancer Population Not yet recruiting NCT05512767
68 Effects of Early vs Late Onset of Swallowing Exercises on Patients Undergoing Radiation Treatment for Head and Neck Cancer Terminated NCT01053546
69 A Pilot Study Assessing Transoral Robotic Surgery (TORS) For Oral And Laryngopharyngeal Benign And Malignant Lesions Using The da Vinci® Robotic Surgical System Terminated NCT00721539
70 Accuracy of Endoscopic Diagnosis of Carcinoma of the UpperAerodigestive Tract: A Tandem Trial of Direct Rigid Endoscopy and Transnasal Flexible Endoscopy With Narrowband Imaging Withdrawn NCT01175499

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Genetic Tests for Hypopharynx Cancer

Anatomical Context for Hypopharynx Cancer

Organs/tissues related to Hypopharynx Cancer:

FMA: Hypopharynx
MalaCards : Lymph Node, Tongue, Endothelial, Thyroid, Skin, Bone Marrow, T Cells

Publications for Hypopharynx Cancer

Articles related to Hypopharynx Cancer:

(showing 1992, show less)
# Title Authors PMID Year
1
miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). 46
20700123 2010
2
[Expression of CD44 and nm23-H1 protein in the primary and metastatic lymph node lesions in supraglottic and hypopharyngeal cancer]. 53 62
16848180 2006
3
Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma. 53 62
16308260 2006
4
Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma. 53 62
9555115 1998
5
Severe obstructive sleep apnea after concurrent chemoradiotherapy for laryngeal and hypopharyngeal cancer managed by CPAP. 62
34108099 2022
6
Oncological outcomes from surgical vs. non-surgical treatments for advanced hypopharyngeal squamous cell carcinoma: a surveillance, epidemiology, and end results-based study. 62
35882729 2022
7
Outcomes of surgical versus non-surgical treatment of resectable T4a laryngeal and hypopharyngeal carcinoma. 62
35300741 2022
8
Role of immune-inflamed phenotype in the prognosis of hypopharyngeal carcinoma following primary surgery. 62
36222335 2022
9
Delta-volume radiomics of induction chemotherapy to predict outcome of subsequent chemoradiotherapy for locally advanced hypopharyngeal cancer. 62
34423708 2022
10
RELA is required for CD271 expression and stem-like characteristics in hypopharyngeal cancer. 62
36273237 2022
11
Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma. 62
36261585 2022
12
Association between γ-Glutamyltransferase and Head and Neck Cancer in Korean Population: A National Population-Based Study. 62
35944063 2022
13
A new nomogram to predict oncological outcome in laryngeal and hypopharyngeal carcinoma patients after laryngopharyngectomy. 62
36183023 2022
14
Tracheostomy dependence following "organ preservation" (chemo)radiation protocol for laryngeal and hypopharyngeal cancers. 62
36121012 2022
15
A rare case of Pseudomonas aeruginosa enteritis induced by pembrolizumab. 62
36114073 2022
16
[Application of transverse cervical artery flap in laryngeal function preservation surgery of hypopharyngeal carcinoma]. 62
36111478 2022
17
Evaluation of chronological changes in videofluorographic findings after transoral videolaryngoscopic surgery to reveal mechanism of dysphagia. 62
36075789 2022
18
Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival. 62
36173618 2022
19
Reducing complications in reconstruction of the cervical esophagus with anterolateral thigh flap: The five points protocol. 62
35614011 2022
20
Stabilization of DEPTOR sensitizes hypopharyngeal cancer to radiotherapy via targeting degradation. 62
36090478 2022
21
Survival and swallowing function outcome impact factors analysis of surgery-oriented comprehensive treatment for hypopharyngeal cancer in a series of 122 patients. 62
34792398 2022
22
Impact of prior cancer history on survival of patients with hypopharyngeal cancer. 62
36057955 2022
23
Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma. 62
35915867 2022
24
The management of metastatic neck nodes following induction chemotherapy in N2/3 classification hypopharyngeal carcinoma. 62
35915865 2022
25
Oncological and functional outcomes of transoral laser surgery for hypopharyngeal carcinoma. 62
36056169 2022
26
Hypopharyngeal carcinoma in Finland from 2005 to 2014: outcome remains poor after major changes in treatment. 62
36094562 2022
27
Adipofascial anterolateral thigh free flap in hypopharyngeal and oropharyngeal reconstruction. 62
35043476 2022
28
[The effect of cervical lymph node metastasis density on prognosis of hypopharyngeal carcinoma]. 62
36058662 2022
29
Lentivirus-Mediated Short Hairpin RNA for Follistatin Downregulation Suppresses Tumor Progression in Hypopharyngeal Carcinoma. 62
35864413 2022
30
Deep learning approach of diffusion-weighted imaging as an outcome predictor in laryngeal and hypopharyngeal cancer patients with radiotherapy-related curative treatment: a preliminary study. 62
35201406 2022
31
A Transient Inferolateral ST-Segment Elevation on the Electrocardiogram Due to an Iatrogenic Left-Sided Pneumothorax After an Urgent Tracheostomy in a Patient with Metastatic Hypopharynx Cancer. 62
35976243 2022
32
Montgomery Salivary Bypass Tube in Head and Neck Cancer: The Experience of Our Otolaryngology Clinic. 62
33044843 2022
33
Nivolumab for recurrent/metastatic hypopharyngeal squamous cell carcinoma in a liver transplant recipient. 62
33612350 2022
34
Using the larynx as a last resort for oral intake in a hypopharyngeal cancer patient. 62
33455818 2022
35
Pepper Alkaloid Piperine Increases Radiation Sensitivity of Cancer Cells from Glioblastoma and Hypopharynx In Vitro. 62
35955682 2022
36
Biophysical properties of the neck skin indicating potential complications of salvage surgery for laryngeal/hypopharyngeal cancer. 62
36089862 2022
37
Redo Aortic Valve Replacement With Perceval Prosthesis via Minithoracotomy in a Patient With Permanent Tracheostoma and Tracheoesophageal Shunt. 62
35786016 2022
38
Outcomes for Organ Preservation with Chemoradiation Therapy for T4 Larynx and Hypopharynx Cancer. 62
35801573 2022
39
Therapeutic strategies, oncologic and swallowing outcomes and their predictive factors in patients with locally advanced hypopharyngeal cancer. 62
35076745 2022
40
Near complete response to a pembrolizumab-based therapeutic strategy in an abdominal metastatic head and neck squamous cell carcinoma case. 62
35878084 2022
41
Motivation to smoking cessation in head and neck cancer and dysplasia patients in confrontation with the attitudes of otorhinolaryngologists in delivering anti-smoking therapies. 62
34893934 2022
42
Vasospastic Angina: An Immune-related Adverse Event. 62
34866103 2022
43
Nutritional status at diagnosis is prognostic for pharyngeal cancer patients: a retrospective study. 62
35076744 2022
44
Risk Factors for Feeding Tube Dependency in Patients Undergoing Function Preservation Surgery for Advanced-Stage Laryngohypopharyngeal Cancer. 62
35779157 2022
45
Biomarker discovery for practice of precision medicine in hypopharyngeal cancer: a theranostic study on response prediction of the key therapeutic agents. 62
35841085 2022
46
Pretherapy platelet-to-lymphocyte ratio as a prognostic parameter for locally advanced hypopharyngeal cancer patients treated with radiotherapy combined with chemotherapy. 62
35849189 2022
47
The Usefulness of Machine Learning-Based Evaluation of Clinical and Pretreatment [18F]-FDG-PET/CT Radiomic Features for Predicting Prognosis in Hypopharyngeal Cancer. 62
35864282 2022
48
Postoperative serum C-reactive protein dynamics after pharyngolaryngectomy with jejunal free-flap reconstruction. 62
35904323 2022
49
Nivolumab-induced tracheobronchial chondritis in a patient with hypopharyngeal cancer. 62
35909308 2022
50
HOXA11-AS1 Promotes PD-L1-Mediated Immune Escape and Metastasis of Hypopharyngeal Carcinoma by Facilitating PTBP1 and FOSL1 Association. 62
35954358 2022
51
TIPE2 inhibits migration and promotes apoptosis as a tumor suppressor in hypopharyngeal carcinoma. 62
35894468 2022
52
Computed tomography-based radiomics signature as a pretreatment predictor of progression-free survival in locally advanced hypopharyngeal carcinoma with a different response to induction chemotherapy. 62
35212776 2022
53
Oncological Analysis and Surgical Outcomes in Postcricoid Carcinoma: A 14 Years Retrospective Study. 62
35804918 2022
54
The effect of HPV DNA and p16 status on the prognosis of patients with hypopharyngeal carcinoma: a meta-analysis. 62
35705893 2022
55
A Nomogram to Predict Nodal Response after Induction Chemotherapy for Hypopharyngeal Carcinoma. 62
35699589 2022
56
Efficacy evaluation of different measurement methods for target lesions after neoadjuvant chemotherapy and radical radiotherapy in locally advanced hypopharyngeal carcinoma. 62
35692104 2022
57
RAF1 promotes lymphatic metastasis of hypopharyngeal carcinoma via regulating LAGE1: an experimental research. 62
35668458 2022
58
Prognostic factors and the role of locoregional treatment in patients with distantly metastatic hypopharyngeal cancer: a retrospective cohort study based on SEER database. 62
35073716 2022
59
Experience with Photodynamic Therapy Using Indocyanine Green Liposomes for Refractory Cancer. 62
35887536 2022
60
Voice outcomes in patients with advanced laryngeal and hypopharyngeal cancer treated with chemo-radiotherapy. 62
35880365 2022
61
Surgeon Volume and Laryngectomy Outcomes. 62
35634691 2022
62
Advanced hypopharyngeal squamous cell carcinoma mimicking thyroid abscess in a young male: Case report and literature review. 62
35658311 2022
63
CT-based radiomics signature analysis for evaluation of response to induction chemotherapy and progression-free survival in locally advanced hypopharyngeal carcinoma. 62
35608663 2022
64
Health-Related Quality of Life, Dysphagia, Voice Problems, Depression, and Anxiety After Total Laryngectomy. 62
34490903 2022
65
Sex Differences in the Prevalence of Head and Neck Cancers: A 10-Year Follow-Up Study of 10 Million Healthy People. 62
35626129 2022
66
Expression of LATS1 in head and neck squamous cell carcinoma and its effect on tumor cell proliferation and invasion. 62
36029506 2022
67
Efficacy of Larynx Preservation Surgery and Multimodal Adjuvant Therapy for Hypopharyngeal Cancer: A Case Series Study. 62
35537143 2022
68
Endoscopic Submucosal Dissection for a Giant Well-Differentiated Liposarcoma Originated from Hypopharynx. 62
35545853 2022
69
Swallowing function improvement using costal cartilage for severe dysphagia after supracricoid hemilaryngopharyngectomy. 62
35606217 2022
70
Noxious Combination of Tobacco Smoke Nitrosamines with Bile, Deoxycholic Acid, Promotes Hypopharyngeal Squamous Cell Carcinoma, via NFκB, In Vivo. 62
35502554 2022
71
Minocycline-induced black thyroid with black pigmentation of the thyroid cartilage, cricoid cartilage, and trachea found during reconstructive surgery for hypopharyngeal cancer. 62
32912766 2022
72
Osteoradionecrosis of the cervical spine: an uncommon complication of radiation therapy for hypopharyngeal cancer. 62
35387787 2022
73
MicroRNA-29a-3p regulates chemosensitivity in hypopharyngeal carcinoma via targeting Cdc42. 62
35484886 2022
74
First Case of Esophagectomy Using a Robotic Single-Port System for Laryngo-Esophagectomy. 62
35135905 2022
75
Total Pharyngo-Laryngo-Cervical-Esophagectomy with Jejunal Free Flap Reconstruction in a Developing Country: A Case Report from Vietnam. 62
35342189 2022
76
A risk factor for newly diagnosed secondary cancer in patients with early-stage laryngeal, oropharyngeal, or hypopharyngeal cancer: sub-analysis of a prospective observation study. 62
34787745 2022
77
Preservation of Internal Branch of Superior Laryngeal Nerve during Surgery for Hypopharyngeal Cancer. 62
32804572 2022
78
Postoperative Complications and Swallowing Function after Jejunal and Skin Flap Reconstruction for Hypopharyngeal Carcinoma-A Multicenter Retrospective Study. 62
35268555 2022
79
Actinidia chinensis Planch Root extract suppresses the growth and metastasis of hypopharyngeal carcinoma by inhibiting E2F Transcription Factor 1-mediated MNX1 antisense RNA 1. 62
35152841 2022
80
The effect of photodynamic therapy on head and neck squamous cell carcinoma cell lines using spirulina platensis with different laser energy densities. 62
34910993 2022
81
Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan. 62
35029329 2022
82
Incidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century. 62
35236321 2022
83
Blood Group Type Association with Head and Neck Cancer. 62
35323176 2022
84
Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. 62
35322907 2022
85
Quality of life and tracheostomy influence in successfully treated hypopharyngeal cancer: A case report. 62
35126698 2022
86
Correction of carotid artery stenosis by stent placement ameliorated paroxysmal hypertension after radiation treatment of hypopharyngeal carcinoma: a case report. 62
35172903 2022
87
Assessing the Applicability of the TALK Score: A Modification for Concurrent Tobacco Use During Treatment. 62
34126807 2022
88
MR Imaging of Laryngeal and Hypopharyngeal Cancer. 62
34802581 2022
89
Asymptomatic swallowing disorders may be present in individuals with laryngeal and hypopharyngeal cancer treated with chemo-radiotherapy. 62
33963434 2022
90
Psychosocial outcomes of human papillomavirus (HPV)- and non-HPV-related head and neck cancers: A longitudinal study. 62
35122670 2022
91
Evaluation of the prevalence of metachronous second primary malignancies in hypopharyngeal carcinoma and their effect on outcomes. 62
35080148 2022
92
Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer. 62
35181217 2022
93
[Research progress in CT-based radiomics constructing hypopharyngeal cancer and multisystem tumor prediction model]. 62
35172558 2022
94
Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma. 62
35191967 2022
95
Carotid blowout-a rare but fatal complication of endoscopic submucosal dissection of superficial hypopharyngeal carcinoma after radiotherapy. 62
32883576 2022
96
[Survival outcomes and prognostic factors of patients with salvage surgery for hypopharyngeal carcinoma after radiotherapy]. 62
35196763 2022
97
A Case of Acquired Factor V Inhibitor Following Nivolumab Administration. 62
35242461 2022
98
Risk Stratification of Dysphagia After Surgical Treatment of Hypopharyngeal Cancer. 62
35662815 2022
99
Oncological and Functional Outcomes of Larynx-preserving Surgery for Hypopharyngeal Cancer: A Comparison with Definitive Radiation-based Treatment. 62
33781050 2022
100
Hypopharyngeal Reconstruction: Possibilities, Outcomes, and Updates for Improving the Human Health for Quality of Life. 62
35178078 2022
101
Carvacrol Arrests the Proliferation of Hypopharyngeal Carcinoma Cells by Suppressing Ornithine Decarboxylase and Hyaluronidase Activities. 62
35464036 2022
102
Downregulation of S100A9 Reverses Cisplatin-Resistance and Inhibits Proliferation and Migration in Hypopharyngeal Carcinoma. 62
36072966 2022
103
Apatinib and Ginsenoside-Rb1 Synergetically Control the Growth of Hypopharyngeal Carcinoma Cells. 62
35069931 2022
104
[Retrospective analysis on 77 cases of T4b hypopharyngeal carcinoma treated by non-surgical treatments]. 62
35090205 2022
105
A Novel Overall Survival Nomogram Prediction of Secondary Primary Malignancies after Hypopharyngeal Cancer: A Population-Based Study. 62
35528241 2022
106
Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Squamous Cell Carcinomas Identifies KMT2C as a Potential Tumor Suppressor. 62
35664801 2022
107
In-Hospital and Long-Term Outcomes in Patients with Head and Neck Cancer Bleeding. 62
35208501 2022
108
Positron emission tomography and magnetic resonance imaging combined with computed tomography in tumor volume delineation: A case report. 62
35071524 2022
109
Case Report: First-Line Immunotherapy for Esophageal Squamous Carcinoma Combined With Hypopharyngeal Squamous Carcinoma Yields Sustained Survival Benefit. 62
35898511 2022
110
Antagonizing Sec62 function in intracellular Ca2+ homeostasis represents a novel therapeutic strategy for head and neck cancer. 62
36045752 2022
111
Clown Nose: A Rare Hypopharyngeal Cancer Metastasis. 62
34983248 2022
112
Three cases of non-occlusive mesenteric ischemia that developed after head and neck cancer therapy. 62
32723598 2021
113
Algorithmic Approach Using Negative Pressure Wound Therapy Improved Survival for Patients with Synchronous Hypopharyngeal and Esophageal Cancer Undergoing Pharyngolaryngoesophagectomy with Gastric Tube Reconstruction. 62
34585295 2021
114
Intra-arterial chemotherapy targeting metastatic cervical lymph nodes in head and neck cancer. 62
34825623 2021
115
Trends in Treatment of Head and Neck Cancer in Germany: A Diagnosis-Related-Groups-Based Nationwide Analysis, 2005-2018. 62
34885170 2021
116
Up-front neck dissection followed by chemoradiotherapy for T1-T3 hypopharyngeal cancer with advanced nodal involvement. 62
34549854 2021
117
Home-based psychological nursing interventions for improvement of sleep quality and psychological health in patients with hypopharyngeal carcinoma undergoing surgical resections: a randomized trial. 62
35016426 2021
118
Targeting PD-L1 (Programmed death-ligand 1) and inhibiting the expression of IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) affect the proliferation and apoptosis of hypopharyngeal carcinoma cells. 62
34608837 2021
119
Oropharynx microbiota transitions in hypopharyngeal carcinoma treatment of induced chemotherapy followed by surgery. 62
34753420 2021
120
Continuous Conversion of CT Kernel Using Switchable CycleGAN With AdaIN. 62
33950836 2021
121
A Novel Technique of Negative Pressure Wound Therapy for Pharyngeal Cutaneous Fistulas Around Tracheostomas. 62
34224456 2021
122
Thoracoscopic total laryngo-pharyngo-oesophagectomy for the pharyngoesophageal junction cancer: a single-center experience of multidisciplinary team. 62
33651150 2021
123
Lung metastases in newly diagnosed hypopharyngeal cancer: a population-based study. 62
33599844 2021
124
Prognostic Factors of Potential Early Recurrence of Hypopharyngeal Carcinoma. 62
34732449 2021
125
The impact of second-hand smoke on ear, nose, and throat diseases and head and neck cancers in Japan: a cross-sectional study using a questionnaire and secondary data from the national health and nutrition survey. 62
34669563 2021
126
Bile reflux and hypopharyngeal cancer (Review). 62
34558652 2021
127
Local random flaps for cervical circumferential defect or tracheoesophageal fistula reconstruction after failed gastric pull-up: Two case reports. 62
34904107 2021
128
A Case of Hypopharyngeal Cancer Associated With Fanconi Anemia: A Helical Tomotherapy Experience. 62
34925988 2021
129
Tracking changes in age distribution of head and neck cancer in the United States from 1975 to2016. 62
34075701 2021
130
Circ_0058106 promotes proliferation, metastasis and EMT process by regulating Wnt2b/β-catenin/c-Myc pathway through miR-185-3p in hypopharyngeal squamous cell carcinoma. 62
34750351 2021
131
A case of diffuse aspiration bronchiolitis due to oesophageal stenosis after radiation therapy. 62
34631103 2021
132
Prognostic significance of human papillomavirus status and treatment modality in hypopharyngeal cancer. 62
34165223 2021
133
Single-port transoral robotic surgery hypopharyngectomy. 62
34156733 2021
134
A Need for a Diagnostic Management Protocol in Barium Aspiration. 62
33896861 2021
135
Image-enhanced endoscopy for detection of second primary esophageal neoplasms in patients with hypopharyngeal cancer: Prevalence, risk factors, and characteristics. 62
34320514 2021
136
Hypopharyngeal reconstruction with gastro-omental free flap. 62
33431349 2021
137
Gel spacer to protect carotid artery and reconstructed jejunum in image-guided interstitial brachytherapy for recurrent hypopharyngeal cancer: a technical report. 62
34759983 2021
138
Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study. 62
34329867 2021
139
Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB. 62
34418696 2021
140
Serum-derived exosomes promote CD8+ T cells to overexpress PD-1, affecting the prognosis of hypopharyngeal carcinoma. 62
34717645 2021
141
[Retrospective study of thyroid invasion and central lymph node metastasis in 124 patients with hypopharyngeal carcinoma]. 62
34666444 2021
142
Surgical treatment of T2-3 posterior hypopharyngeal carcinoma with preservation of laryngeal function. 62
34459710 2021
143
Treatment effect of concurrent chemoradiotherapy after surgery and its effect on postoperative swallowing function of patients with locally advanced hypopharyngeal carcinoma. 62
34761610 2021
144
The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. 62
31882379 2021
145
Should upfront surgery routinely be the treatment of choice for locoregionally advanced hypopharyngeal cancer in 2021? 62
34131915 2021
146
Author's reply regarding the letter to the editor about our article: A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0. 62
34268595 2021
147
Letter to the editor "A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0". 62
33786657 2021
148
[Repair of large pharyngeal fistula after multidisciplinary therapy of advanced hypopharyngeal carcinoma: a case report]. 62
34666451 2021
149
Massive upper gastrointestinal bleeding secondary to an esophago-arterial fistula (arteria lusoria). 62
33569959 2021
150
Mediastinal Lymph Node Metastasis from Head and Neck Cancer: Predictive Factors and Imaging Features. 62
36238410 2021
151
Evaluation of Pharyngeal Background Mucosa in Patients with Superficial Hypopharyngeal Carcinoma. 62
33729575 2021
152
HPV Status as Prognostic Biomarker in Head and Neck Cancer-Which Method Fits the Best for Outcome Prediction? 62
34572957 2021
153
Modelling the number of avoidable new cancer cases in France attributable to alcohol consumption by following official recommendations: a simulation study. 62
33565659 2021
154
Preoperative MRI Evaluation of Thyroid Cartilage Invasion in Patients with Laryngohypopharyngeal Cancer: Comparison of Contrast-Enhanced 2D Spin-Echo and 3D T1-Weighted Radial Gradient Recalled-Echo Techniques. 62
34301638 2021
155
A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0. 62
33566179 2021
156
A simple but unusual rearrangement of an oleanane to a taraxerane-28,14 β -olide. 62
33930390 2021
157
Detection of human papillomavirus infection in laryngeal and hypopharyngeal carcinoma using droplet digital PCR and its correlation with prognosis. 62
33754942 2021
158
Prognostic factors after transoral resection of early hypopharyngeal cancer. 62
34401500 2021
159
Family History of Head and Neck Cancers. 62
34439270 2021
160
Tunicamycin-induced endoplasmic reticulum stress inhibits chemoresistance of FaDu hypopharyngeal carcinoma cells in 3D collagen I cultures and in vivo. 62
34224701 2021
161
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial. 62
34256319 2021
162
Punicic Acid Triggers Ferroptotic Cell Death in Carcinoma Cells. 62
34444911 2021
163
Results of pretreatment swallowing evaluation in patients with stage III/IV laryngeal and hypopharyngeal carcinoma. 62
33165732 2021
164
Postoperative Complications of Jejunal and Skin Valve Reconstruction in Free Reconstructive Surgery for Hypopharyngeal Carcinoma. 62
34281870 2021
165
Intravoxel Incoherent Motion Magnetic Resonance Imaging for Prediction of Induction Chemotherapy Response in Locally Advanced Hypopharyngeal Carcinoma: Comparison With Model-Free Dynamic Contrast-Enhanced Magnetic Resonance Imaging. 62
33576125 2021
166
Pseudoginsengenin DQ exerts antitumour activity against hypopharyngeal cancer cells by targeting the HIF-1α-GLUT1 pathway. 62
34281558 2021
167
Prognostic imaging variables for recurrent laryngeal and hypopharyngeal carcinoma treated with primary chemoradiotherapy: A systematic review and meta-analysis. 62
33797818 2021
168
Editorial for "Intra-voxel incoherent motion (IVIM) MRI for prediction of induction chemotherapy response in locally advanced hypopharyngeal carcinoma: comparison with model-free dynamic contrast-enhanced MRI". 62
33779001 2021
169
Hypopharynx reconstruction for primary hypopharyngeal carcinoma: a retrospective study and literature review. 62
35116630 2021
170
Prognostic significance of hypoxia-inducible factor-1α expression in advanced pharyngeal cancer without human papillomavirus infection. 62
34108057 2021
171
Cyclooxygenase-2 expression is associated with chemoresistance through cancer stemness property in hypopharyngeal carcinoma. 62
34084214 2021
172
Is Increased Time From Diagnosis to Treatment in Advanced Hypopharynx Cancer Associated With Poorer Outcomes: A Single-Centre Analysis. 62
31569981 2021
173
Dissection of Cervical Lymph Node Metastasis With Internal Jugular-Subclavian Venous Junction Invasion Via an Approach Involving Resection of the Margin of the Medial Clavicle. 62
34345545 2021
174
Incessant Atrial Tachycardia Following Combination Chemotherapy with Cetuximab, Cisplatin and 5-Fluorouracil for Hypopharyngeal Cancer. 62
33830451 2021
175
Digestion-Specific Acupuncture Effect on Feeding Intolerance in Critically Ill Post-Operative Oral and Hypopharyngeal Cancer Patients: A Single-Blind Randomized Control Trial. 62
34205461 2021
176
The patient-reported outcome measures in oropharyngeal, laryngeal and hypopharyngeal cancer patients treated with Volumetric Modulated Arc based simultaneous integrated boost radiotherapy. 62
33817354 2021
177
Successful radiotherapy of de novo hypopharyngeal cancer in a Fanconi anemia patient with previous esophageal cancer. 62
34194758 2021
178
Colitis presenting 5 months after the final dose of anti-PD-1: long-term monitoring is warranted after adjuvant therapy. 62
33906378 2021
179
Closing an Intractable Tracheoesophageal Fistula Caused by a Tracheoesophageal Shunt Using a Myocutaneous Flap and a Hinged Flap With Skin Graft in a Two-Step Procedure. 62
34322353 2021
180
To what extent has the last two decades seen significant progress in the management of older patients with head and neck cancer? 62
33648773 2021
181
Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: A case report. 62
34136239 2021
182
Prognostic Significance of Vocal Cord Mobility after Laryngeal Preservation Protocols in Locally Advanced Laryngopharyngeal Cancers: A Retrospective Analysis. 62
34150595 2021
183
Survival and complications with a surgical approach in advanced hypopharyngeal cancer. 62
33621353 2021
184
Speech Performance after Anterolateral Thigh Phonatory Tube Reconstruction for Total Laryngectomy. 62
33280117 2021
185
(+)-Usnic acid modulates the Nrf2-ARE pathway in FaDu hypopharyngeal carcinoma cells. 62
33635505 2021
186
A novel surgical approach for hypopharyngeal carcinoma resection via the paraglottic space. 62
33941151 2021
187
[Postoperative prognostic risk factors and treatment strategies for patients with T3-T4 hypopharyngeal squamous cell carcinoma]. 62
34304462 2021
188
Frequent occurrence of postbreakfast syncope due to carotid sinus syndrome after surgery for hypopharyngeal cancer: A case report. 62
34011078 2021
189
Presurgical platelet-lymphocyte ratio for prognosis in advanced hypopharyngeal squamous cell carcinoma in individuals undergoing radical resection. 62
33872102 2021
190
GPR12 inhibits migration and promotes apoptosis in esophageal cancer and hypopharyngeal cancer cells. 62
33742771 2021
191
Survival Benefits From Surgery for Stage IVa Head and Neck Squamous Cell Carcinoma: A Multi-institutional Analysis of 1,033 Cases. 62
33081440 2021
192
Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure. 62
33933118 2021
193
Predicting Factors for Oncological and Functional Outcome in Hypopharyngeal Cancer. 62
33098325 2021
194
Health-Related Quality of Life Following Total Laryngectomy: A Systematic Review. 62
32866284 2021
195
Matched-Pair Analysis of Survival in the Patients with Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma Treated with Induction Chemotherapy Plus Chemo-Radiation or Total Laryngectomy. 62
33917434 2021
196
Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma. 62
33575927 2021
197
[Surgical treatment of hypopharyngeal carcinoma combined with esophageal carcinoma: analysis of 30 cases]. 62
33794637 2021
198
Retrograde endoscopic submucosal dissection for early thoracic esophageal carcinoma. 62
33689125 2021
199
Magnitude and pattern of various cancers from tertiary health care center registry: A study in three southern states of India. 62
34121674 2021
200
Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis. 62
33909487 2021
201
Evaluation of the usefulness of upper gastrointestinal endoscopy and the ValsamouthⓇ by an otolaryngologist in patients with Hypopharyngeal cancer. 62
32950326 2021
202
An unusual first presentation of hypopharyngeal carcinoma as thyroid abscess: Case report of a diagnostic challenge. 62
33713999 2021
203
Neck dissection prolongs survival in patient with stage IVC hypopharyngeal carcinoma with mixed responses to nivolumab. 62
32173169 2021
204
Nimotuzumab combined with radiotherapy for the treatment of hypopharyngeal cancer - A case report from a tertiary cancer center. 62
34104833 2021
205
The prognostic value of USP7 and p53 in advanced hypopharyngeal carcinoma. 62
33460997 2021
206
Oncological results of salvage treatment in patients with hypopharyngeal carcinoma. 62
32473712 2021
207
Prediction of Disease Free Survival in Laryngeal and Hypopharyngeal Cancers Using CT Perfusion and Radiomic Features: A Pilot Study. 62
33681460 2021
208
Survival and function following pharyngo-laryngo-oesophagectomy in Wales: a twelve-year case series. 62
33509309 2021
209
Application of acellular dermal matrix to reconstruct the defects after hypopharyngeal carcinoma resection. 62
33352492 2021
210
Tumor dimension-dependent microscopic extensions of hypopharyngeal cancer: Therapeutic implications for larynx-preserving hypopharyngectomy. 62
33497489 2021
211
Sandwich-type electrochemical immunosensing of Hypopharyngeal carcinoma biomarker carcinoembryonic antigen based on N-doped hollow mesoporous nanocarbon spheres/gold hybrids as sensing platform and gold/ferrocene as signal amplifier. 62
33678724 2021
212
N6-methyladenosine modification of circCUX1 confers radioresistance of hypopharyngeal squamous cell carcinoma through caspase1 pathway. 62
33741902 2021
213
Analysis of palliative care treatment among head and neck patients with cancer: National perspective. 62
33151575 2021
214
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer. 62
32241084 2021
215
Risk of head and neck cancer in patients with peptic ulcers and the effect of Helicobacter pylori treatment. 62
33737604 2021
216
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report. 62
33768839 2021
217
Prognostic value of radiologic extranodal extension in patients with hypopharyngeal cancer treated with primary chemoradiation. 62
33385465 2021
218
Cutaneous metastasis of a hypopharyngeal squamous cell carcinoma-unusual presentation. 62
33865283 2021
219
Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis. 62
33652909 2021
220
Simultaneous evaluation of symptoms, swallowing functions, and patient-reported swallowing difficulties and their correlations with ingestion status during definitive chemoradiotherapy for oropharyngeal and hypopharyngeal cancer. 62
32556716 2021
221
The incidence of myocardial infarction and stroke in head and neck cancer patients. 62
33603026 2021
222
Improved Tumor Control Related to Radiotherapy Technological Development for Hypopharyngeal Cancer. 62
32396214 2021
223
CD147 promotes invasion and MMP-9 expression through MEK signaling and predicts poor prognosis in hypopharyngeal squamous cell carcinoma. 62
33529506 2021
224
Analysis of Race and Gender Disparities in Mortality Trends from Patients Diagnosed with Nasopharyngeal, Oropharyngeal and Hypopharyngeal Cancer from 2000 to 2017. 62
34629896 2021
225
Different Primary Sites of Hypopharyngeal Cancer Have Different Lymph Node Metastasis Patterns: A Retrospective Analysis From Multi-Center Data. 62
34616679 2021
226
HPV Positive Status Is a Favorable Prognostic Factor in Non-Nasopharyngeal Head and Neck Squamous Cell Carcinoma Patients: A Retrospective Study From the Surveillance, Epidemiology, and End Results Database. 62
34631523 2021
227
Early Mortality after Radical Radiotherapy in Head and Neck Cancer - A Nationwide Analysis from the Danish Head and Neck Cancer Group (DAHANCA) Database. 62
32698963 2021
228
A Case of Progressive Multifocal Leukoencephalopathy in a Fumaric Acid-Treated Psoriasis Patient With Severe Lymphopenia Among Other Risk Factors. 62
34992484 2021
229
The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study. 62
32560605 2021
230
Diabetes insipidus secondary to nivolumab-induced neurohypophysitis and pituitary metastasis. 62
33522491 2021
231
High Pretreatment LDH Predicts Poor Prognosis in Hypopharyngeal Cancer. 62
33777804 2021
232
Oncological and Functional Outcomes of Transoral Robotic Surgery and Endoscopic Laryngopharyngeal Surgery for Hypopharyngeal Cancer: A Systematic Review. 62
35464886 2021
233
Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer. 62
33469045 2021
234
Jejunal and ileocolic free flaps for digestive tract reconstruction following pharyngo-laryngo-oesophagectomy - 30 years of single-centre experience. 62
33911979 2021
235
The incidence of newly diagnosed secondary cancer; sub-analysis the prospective study of the second-look procedure for transoral surgery in patients with T1 and T2 head and neck cancer. 62
32929629 2021
236
Development and Validation of a Prognostic Nomogram for Hypopharyngeal Carcinoma. 62
34235086 2021
237
3-MA Enhanced Chemosensitivity in Cisplatin Resistant Hypopharyngeal Squamous Carcinoma Cells via Inhibiting Beclin -1 Mediated Autophagy. 62
33349212 2021
238
Prognostic value of α2δ1 in hypopharyngeal carcinoma: A retrospective study. 62
34611550 2021
239
Preclinical Application of Conditional Reprogramming Culture System for Laryngeal and Hypopharyngeal Carcinoma. 62
34778255 2021
240
Expression and Functional Relevance of ANXA1 in Hypopharyngeal Carcinoma with Lymph Node Metastasis. 62
33658802 2021
241
Prognostic role of pretreatment albumin-to-alkaline phosphatase ratio in locally advanced laryngeal and hypopharyngeal cancer: Retrospective cohort study. 62
34539891 2021
242
Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study. 62
34858052 2021
243
Retropharyngeal Lymph Node Metastasis Diagnosed by Magnetic Resonance Imaging in Hypopharyngeal Carcinoma: A Retrospective Analysis From Chinese Multi-Center Data. 62
34178636 2021
244
Nursing Observation on the Clinical Efficacy and Toxicity of Lobaplatin Compared with Cisplatin in the Treatment of Locally Advanced Hypopharyngeal Carcinoma Based on Intelligent CT Imaging. 62
34306603 2021
245
Analysis of ceRNA network of differentially expressed genes in FaDu cell line and a cisplatin-resistant line derived from it. 62
34249502 2021
246
Expression and Diagnostic Value of tRNA-Derived Fragments Secreted by Extracellular Vesicles in Hypopharyngeal Carcinoma. 62
34285510 2021
247
[Repair options for surgical defects of locally advanced hypopharyngeal carcinoma]. 62
33342140 2020
248
[Magnifying endoscopy combined with narrow-band imaging for preoperative examination of hypopharyngeal carcinoma]. 62
33342132 2020
249
Value of oesophagoscopy and bronchoscopy in diagnosis of synchronous malignancies in patients with head and neck squamous cell carcinomas. 62
33256662 2020
250
Design and application of submental island flap to reconstruct non-circumferential defect after hypopharyngeal carcinoma resection: a prospective study of 27 cases. 62
32808843 2020
251
ASO Author Reflections: Salvage Total Laryngectomy, the Last Resort for Patients with Residual, Recurrent or Second Primary Laryngeal and Hypopharyngeal Cancer in Times of Nonsurgical Organ Preserving Treatment Strategies. 62
32851516 2020
252
[A single-arm prospective study on induction chemotherapy and subsequent comprehensive therapy for advanced hypopharyngeal squamous cell carcinoma: report of 260 cases in a single center]. 62
33342130 2020
253
[Correctly understanding, scientifically evaluating, and actively promoting standardized treatment of hypopharyngeal cancer]. 62
33342125 2020
254
Simultaneous Endoscopic Resection of Superficial Cancers of the Hypopharynx and Esophagus: A Case Report. 62
32475899 2020
255
[Carotid-subclavian Bypass for Radiation-induced Subclavian Artery Occlusion;Report of a Case]. 62
33271578 2020
256
[Application of rigid curved laryngoscope in the examination of hypopharynx and the treatment of early hypopharyngeal cancer]. 62
33342129 2020
257
[Application of submental artery perforator flap in reconstruction surgery in pharyngeal carcinoma]. 62
33342127 2020
258
Induction chemotherapy for the individualised treatment of hypopharyngeal carcinoma with cervical oesophageal invasion: a retrospective cohort study. 62
33308220 2020
259
Human Bone Marrow Mesenchymal Stem Cells Modified Hybrid Baculovirus-Adeno-Associated Viral Vectors Targeting 131I Therapy of Hypopharyngeal Carcinoma. 62
32940055 2020
260
Effect of Periodontitis and Scaling and Root Planing on Risk of Pharyngeal Cancer: A Nested Case-Control Study. 62
33375028 2020
261
Unplanned hospitalizations in patients with locoregionally advanced head and neck cancer treated with (chemo)radiotherapy with and without prophylactic percutaneous endoscopic gastrostomy. 62
33317602 2020
262
Predictors of Weight Loss in Patients With Head and Neck Cancer Receiving Radiation or Concurrent Chemoradiation Treated at a Tertiary Cancer Center. 62
32329543 2020
263
Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience. 62
32671892 2020
264
A 25-year Experience at an Academic Medical Center in the United States: Are There Racial Disparities in the Prognosis of Patients Diagnosed With Hypopharyngeal Carcinoma? 62
33282583 2020
265
Vascular events from carotid artery atherosclerosis after radiation therapy for laryngeal and hypopharyngeal cancer: the incidence and risk factors. 62
33311805 2020
266
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer. 62
32915647 2020
267
Treatment sequence and survival in locoregionally advanced hypopharyngeal cancer: A surveillance, epidemiology, and end results-based study. 62
31821572 2020
268
Myosin light chain kinase is a potential target for hypopharyngeal cancer treatment. 62
32920510 2020
269
Immune related proteins and tumor infiltrating CD8+ lymphocytes in hypopharyngeal cancer in relation to human papillomavirus (HPV) and clinical outcome. 62
32613643 2020
270
Gender Disparities in Epidemiology, Treatment, and Outcome for Head and Neck Cancer in Germany: A Population-Based Long-Term Analysis from 1996 to 2016 of the Thuringian Cancer Registry. 62
33218009 2020
271
[Application strategy and effect of cuffed tracheostomy tube with inner cannula in the treatment of postoperative complications of laryngeal or hypopharyngeal cancer]. 62
33256313 2020
272
Analysis of vascular-associated factors and the prognosis of poorly differentiated hypopharyngeal carcinoma. 62
32989405 2020
273
Synchronous reconstruction of esophageal defect and voice with J-flap after laryngopharyngectomy: Indications and outcomes. 62
32836094 2020
274
Bone Marrow Mesenchymal Stem Cells Promote the Stemness of Hypopharyngeal Cancer Cells. 62
32833513 2020
275
Scar contracture prevention with local steroid injections in transoral videolaryngoscopic surgery. 62
32107068 2020
276
Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer: A meta-analysis with trial sequential analysis. 62
32422386 2020
277
MiR-338-3p inhibits cell migration and invasion in human hypopharyngeal cancer via downregulation of ADAM17. 62
32889897 2020
278
Prognostic role of human papilloma virus status in hypopharyngeal squamous cell carcinoma. 62
33134533 2020
279
["Point line anterograde dissection" for the safe preparation of supraclavicular flap]. 62
32911887 2020
280
Risk factors associated with the development of aspiration pneumonia in patients receiving radiotherapy for head and neck cancer: retrospective study. 62
32478453 2020
281
Risk factors of head and neck cancer mortality compared with those of all-cause and all-cancer mortalities. 62
32624546 2020
282
Is the risk of idiopathic sudden sensorineural hearing loss higher in nasopharyngeal carcinoma than in hypopharyngeal cancer? A population-based study. 62
32221154 2020
283
Comparison of Quality of Life among Patients with Oro-Hypopharyngeal Cancer after Tonsillectomy and Panscopy Using Transoral Robotic Surgery: A Pilot Study. 62
33250745 2020
284
Optimizing Survival Predictions of Hypopharynx Cancer: Development of a Clinical Prediction Model. 62
31693181 2020
285
Prognostic value of HPV status among patients with hypopharyngeal carcinoma: a population-based study. 62
31939101 2020
286
The temporal effects of topical NF-κB inhibition, in the in vivo prevention of bile-related oncogenic mRNA and miRNA phenotypes in murine hypopharyngeal mucosa: a preclinical model. 62
32934775 2020
287
Prediction of Results of Radiotherapy With Ku70 Expression and an Artificial Neural Network. 62
32871826 2020
288
Invited commentary on "Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer; a meta-analysis with trial sequential analysis" (Int J Surg 2020; Epub ahead of print). 62
32682977 2020
289
[Organ preservation in advanced laryngeal/hypopharyngeal carcinoma: lessons from the DeLOS-II trial]. 62
32468135 2020
290
Invited commentary on "Initial surgical versus non-surgical treatments for advanced hypopharyngeal cancer: A meta-analysis with trial sequential analysis". 62
32535262 2020
291
Surgical removal of solitary cardiac metastasis of hypopharyngeal cancer. 62
32227241 2020
292
Lateral conservative approach for recurrent/persistent hypopharyngeal carcinoma: a case series. 62
32367150 2020
293
[Chinese expert consensus on multiple primary cancers of hypopharynx and esophagus]. 62
32727188 2020
294
[The impact of surgical treatment on the life quality of patients with locally advanced hypopharyngeal carcinoma]. 62
32867463 2020
295
Involvement of Differentially Expressed microRNAs in the PEGylated Liposome Encapsulated 188Rhenium-Mediated Suppression of Orthotopic Hypopharyngeal Tumor. 62
32784458 2020
296
[Analysis of key genes and signal pathways of human papilloma virus-related head and neck squamous cell carcinoma]. 62
32842349 2020
297
Prevention of upper aerodigestive tract cancer through active search strategies and use of equipped propaedeutics. 62
30837188 2020
298
Neoadjuvant chemotherapy as a comprehensive treatment in patients with laryngeal and hypopharyngeal carcinoma. 62
32186224 2020
299
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy using volumetric-modulated arc therapy as an organ preservation approach in patients with stage IVA-B oropharyngeal or hypopharyngeal cancers. 62
32548612 2020
300
A Single Institution's Experience of Definitive Radiotherapy Using Volumetric-modulated Arc Therapy for Hypopharyngeal Cancers. 62
32620668 2020
301
Utility of Valsalva maneuver in the endoscopic pharyngeal observation. 62
32072359 2020
302
Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial. 62
32454417 2020
303
Comparison of diagnostic performance between CT and MRI for detection of cartilage invasion for primary tumor staging in patients with laryngo-hypopharyngeal cancer: a systematic review and meta-analysis. 62
32152744 2020
304
Follow up imaging of oral, oropharyngeal and hypopharyngeal cancer patients: Comparison of PET-CT and MRI post treatment. 62
32513432 2020
305
Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells. 62
32680979 2020
306
Mortality Among Firefighters in Spain: 10 Years of Follow-up. 62
32253442 2020
307
Comparative Study Between Integrated Positron Emission Tomography/Magnetic Resonance and Positron Emission Tomography/Computed Tomography in the T and N Staging of Hypopharyngeal Cancer: An Initial Result. 62
32558774 2020
308
[Determination of pathological margin of hypopharyngeal cancer by terahertz time-domain spectroscopy system]. 62
32791642 2020
309
"End to Side Technique": More organ preservation with less morbidity in patients with pyriform sinus apex SCC. 62
32354480 2020
310
Induction Chemotherapy in Hypopharyngeal Cancer: Influence of DNA Repair Gene Polymorphisms. 62
32487623 2020
311
Quantifying the impact of optical surface guidance in the treatment of cancers of the head and neck. 62
32250046 2020
312
Expression of let-7i and miR-192 is associated with resistance to cisplatin-based chemoradiotherapy in patients with larynx and hypopharynx cancer. 62
32585557 2020
313
Diagnosis and Monitoring Value of Diffusion-Weighted Magnetic Resonance Imaging Using Neuroendocrine Analysis During Radiotherapy for Laryngeal Cancer. 62
31931239 2020
314
Feasibility and effectiveness of palliative intensity-modulated radiotherapy for carotid sinus syndrome secondary to recurrent head and neck cancer. 62
32606123 2020
315
Mortality from Selected Cancers among Brazilian Mechanics. 62
32592378 2020
316
[Semi-free transverse cervical artery flap for repairing defects after head and neck tumor resection]. 62
32842180 2020
317
The role of bile reflux and its related NF-κB activated pathway in progression of hypopharyngeal squamous cell cancer. 62
32247988 2020
318
Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report. 62
32580711 2020
319
HCV infection and the risk of head and neck cancer: A meta-analysis. 62
32599500 2020
320
Welding and the risk of head and neck cancer: the ICARE study. 62
31959638 2020
321
Surgical rescue for persistent head and neck cancer after first-line treatment. 62
31982945 2020
322
Longitudinal atherosclerotic changes after radio(chemo)therapy of hypopharyngeal carcinoma. 62
32381045 2020
323
Surgical nodal management in hypopharyngeal and laryngeal cancer. 62
32048029 2020
324
[Clinical advances in larynx-preservation management in advanced hypopharyngeal carcinoma]. 62
32842377 2020
325
Effect of up-regulation of circMATR3 on the proliferation, metastasis, progression and survival of hypopharyngeal carcinoma. 62
32166857 2020
326
Tumor cell viability in salvage neck dissections: Poor prognosis predicted by high postradiation nodal SUVmax , p16-negativity, and low nodal shrinkage. 62
31854495 2020
327
Transoral videolaryngoscopic surgery for laryngeal and hypopharyngeal cancer - Technical updates and long-term results. 62
31564510 2020
328
Analysis of patients who decline treatment for squamous cell carcinoma of the head and neck: National perspective. 62
31895475 2020
329
Intranodal lymphangiography for chyle leakage after esophagectomy: A case report. 62
32190317 2020
330
Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study. 62
32213095 2020
331
Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma. 62
31845736 2020
332
Treatment of hypopharyngeal carcinoma complicated with diabetic nephropathy: a case report and literature review. 62
35117551 2020
333
Head and Neck Microvascular Reconstruction in Puerto Rico: Developing a Two-team approach to Microvascular Reconstructive Surgery. 62
32383570 2020
334
Blocking long noncoding RNA MALAT1 restrained the development of laryngeal and hypopharyngeal carcinoma. 62
31792655 2020
335
Prognostic value of the radiomics-based model in progression-free survival of hypopharyngeal cancer treated with chemoradiation. 62
31673835 2020
336
Indian clinical practice consensus guidelines for the management of hypopharyngeal cancer. 62
32167067 2020
337
Severe late dysphagia after multimodal treatment of stage III/IV laryngeal and hypopharyngeal cancer. 62
31711185 2020
338
Detection of hypopharyngeal cancer (Tis, T1 and T2) by ENT physicians vs gastrointestinal endoscopists. 62
31153665 2020
339
Systematic review and meta-analysis of transoral laser microsurgery in hypopharyngeal carcinoma. 62
32128432 2020
340
PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. 62
31957270 2020
341
Comparison of xenogeneic acellular dermal matrix and skin grafts in reconstruction of postoperative defects of hypopharyngeal cancer: A retrospective cohort study. 62
32118779 2020
342
[Analysis for potential targeting genes of TPF regimen induction chemotherapy in hypopharyngeal squamous cell carcinoma]. 62
32074750 2020
343
[Meta-analysis of comparison for efficacies between surgical plus radio(chemo)therapy and non-surgery chemoradiotherapy treatment strategies for advanced hypopharyngeal cancer]. 62
32074753 2020
344
[Changing trend in prognosis of primary hypopharyngeal carcinoma and reason analysis: date comparison of 2003-2007 and 2010-2014 in a single centre]. 62
32074749 2020
345
Interstitial diffuse optical probe with spectral fitting to measure dynamic tumor hypoxia. 62
32095273 2020
346
The Efficacy of Low Postoperative Radiation Dose in Patients with Advanced Hypopharyngeal Cancer without High-Risk Factors. 62
32943918 2020
347
Endoscopic submucosal dissection for superficial hypopharyngeal cancer with thin endoscope. 62
31691372 2020
348
Gene sequencing and expression of Raf-1 in lymphatic metastasis of hypopharyngeal carcinoma. 62
32224526 2020
349
A Nomogram for Pretreatment Prediction of Response to Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma. 62
33363001 2020
350
Silencing Snail Reverses Epithelial-Mesenchymal Transition and Increases Radiosensitivity in Hypopharyngeal Carcinoma. 62
32021293 2020
351
Lymph node ratio as a prognostic marker in advanced laryngeal and hypopharyngeal carcinoma after primary total laryngopharyngectomy. 62
31660699 2020
352
Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China. 62
32494195 2020
353
Discovery and Validation of a CT-Based Radiomic Signature for Preoperative Prediction of Early Recurrence in Hypopharyngeal Carcinoma. 62
32851071 2020
354
Corneal Perforation during Combination Chemotherapy including Cetuximab in a Patient with a History of Herpetic Keratitis. 62
32724688 2020
355
TBX3 knockdown suppresses the proliferation of hypopharyngeal carcinoma FaDu cells by inducing G1/S cell cycle arrest and apoptosis. 62
31897121 2020
356
Prostanoid receptor genes confer poor prognosis in head and neck squamous cell carcinoma via epigenetic inactivation. 62
31969157 2020
357
Impact of Magnetic Field on Dose Distribution in MR-Guided Radiotherapy of Head and Neck Cancer. 62
33014859 2020
358
Morphological analysis of ischemia-reperfusion injury in a cold ischemia model of jejunal free flap for hypopharyngeal reconstruction. 62
31494055 2020
359
[Therapy-related acute promyelocytic leukemia with complex karyotype accompanied by cryptic PML/RARA on chromosome 15 by metaphase FISH]. 62
33298649 2020
360
Expression of the long noncoding RNA RP11-169D4.1-001 in Hypopharyngeal Squamous cell carcinoma tissue and its clinical significance. 62
31512299 2020
361
Management of Advanced-stage Hypopharyngeal Carcinoma: 25-Year Experience from a Tertiary Care Medical Center. 62
32104619 2020
362
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer. 62
33173312 2020
363
Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response. 62
31756687 2020
364
Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer. 62
32269737 2020
365
The Clinical Impacts of Pretreatment Peripheral Blood Ratio on Lymphocytes, Monocytes, and Neutrophils Among Patients with Laryngeal/Hypopharyngeal Cancer Treated by Chemoradiation/Radiation. 62
33061596 2020
366
The Pattern of Cervical Lymph Node Metastasis and Risk Factors of Retropharyngeal Lymph Node Metastasis Based on Magnetic Resonance Imaging in Different Sites of Hypopharyngeal Carcinoma. 62
32982450 2020
367
PDK1 promotes metastasis by inducing epithelial-mesenchymal transition in hypopharyngeal carcinoma via the Notch1 signaling pathway. 62
31778670 2020
368
Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer. 62
32341668 2020
369
A nationwide population-based study to access the risk of metachronous esophageal cancers in head and neck cancer survivors. 62
31964952 2020
370
A prospective clinical trial of the second-look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer. 62
31595716 2019
371
Comparative effectiveness of simultaneous integrated boost vs sequential intensity-modulated radiotherapy for oropharyngeal or hypopharyngeal cancer patients: A population-based propensity score-matched analysis. 62
31861029 2019
372
Thiamine deficiency in the bereaved after cancer-related spousal loss. 62
31104649 2019
373
Radiation-induced angiosarcoma of the parotid gland after postoperative radiotherapy for hypopharyngeal carcinoma. 62
30850173 2019
374
[Laryngectomy-still state of the art?] 62
31720696 2019
375
Large neck metastasis of hypopharyngeal cancer. 62
31893118 2019
376
Clinical value of ultrasonic imaging in diagnosis of hypopharyngeal cancer with cervical lymph node metastasis. 62
31788065 2019
377
[62-year-old male with condition following emergency tracheotomy in metastasized hypopharyngeal cancer : Preparation for the medical specialist examination: part 39]. 62
31624883 2019
378
Curved Laryngopharyngoscope With Flexible Next-Generation Robotic Surgical System for Transoral Hypopharyngeal Surgery: A Preclinical Evaluation. 62
31220916 2019
379
Survival differences between definitive radiotherapy and surgery followed by adjuvant radiotherapy in supraglottic and hypopharyngeal carcinoma. 62
31765356 2019
380
Patients with locally advanced hypopharyngeal carcinoma. Results over a 30-year period. 62
30527320 2019
381
Incidence and survival of hypopharyngeal cancer: a Danish Nation-Wide Study from 1980 to 2014. 62
31505992 2019
382
Factors associated with suicidal ideation risk in head and neck cancer: A longitudinal study. 62
30690748 2019
383
Human papillomavirus-associated squamous cell carcinoma of the larynx or hypopharynx: Clinical outcomes and implications for laryngeal preservation. 62
31536842 2019
384
Biliary reflux as a causal factor in hypopharyngeal carcinoma: New clinical evidence and implications. 62
31310330 2019
385
Metastatic lymph node burden predictive of survival in patients undergoing primary surgery for laryngeal and hypopharyngeal cancer. 62
31352569 2019
386
A Survival Analysis of Hypopharyngeal Cancer Patients: A Hospital-Cancer registry Based Study. 62
31742067 2019
387
Treatment results of 99 patients undergoing open partial hypopharyngectomy with larynx preservation. 62
31242294 2019
388
Humanized anti-CD271 monoclonal antibody exerts an anti-tumor effect by depleting cancer stem cells. 62
31325530 2019
389
Clinical outcomes for 61 cases of hypopharyngeal cancer with synchronous esophageal cancer. 62
31251350 2019
390
Successful management of the supraclavicular artery island flap combined with a sternohyoid muscle flap for hypopharyngeal and laryngeal reconstruction. 62
31593117 2019
391
Evaluation of Dynamic CT Scans and Analyzing Its Efficacy Accuracy in Staging of Laryngeal CA: A Prospective Analysis of 30 Patients and Review of Literature. 62
31741971 2019
392
Comparison of Functional Organ Preservation by Concomitant Boost Radiotherapy Versus Concurrent Chemoradiation in Locally Advanced Carcinoma of Larynx or Hypopharynx: A Prospective Randomized Study. 62
31559204 2019
393
[Successful Multidisciplinary Treatment Accomplished by Collaboration of Multiple Clinical Departments for Synchronous Quadruple Cancer]. 62
31506404 2019
394
Evaluation of the information given to patients undergoing total pharyngolaryngectomy and quality of life: a prospective multicentric study. 62
31240456 2019
395
Esophageal Paget's Disease Secondary to Hypopharyngeal Carcinoma: a Case Report. 62
29542074 2019
396
Transoral robotic surgery in patients with stage III/IV hypopharyngeal squamous cell carcinoma: treatment outcome and prognostic factor. 62
31268399 2019
397
The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients. 62
31470817 2019
398
Acupuncture effect on digestion in critically ill postoperative oral and hypopharyngeal cancer patients: A protocol for double-blind randomized control trial. 62
31464933 2019
399
Clinical application of supraclavicular flap for head and neck reconstruction. 62
31139924 2019
400
Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy. 62
31152682 2019
401
Organ Function Preservation Failure after (Chemo)Radiotherapy in Head and Neck Cancer: A Retrospective Cohort Analysis. 62
31060436 2019
402
Safety of esophagogastroduodenoscopy-guided forceps biopsy and the feasibility of esophagogastroduodenoscopy for evaluation of hypopharyngeal cancer. 62
31395049 2019
403
Laryngo-esophageal dysfunction free survival and propensity score matched analysis comparing organ preservation and total laryngectomy in hypopharynx cancer. 62
31345382 2019
404
Textural features on 18F-FDG PET/CT and dynamic contrast-enhanced MR imaging for predicting treatment response and survival of patients with hypopharyngeal carcinoma. 62
31415354 2019
405
[Effect of vascular changes on prognosis after induced chemotherapy for advanced hypopharyngeal carcinoma]. 62
31434372 2019
406
Biliary tumorigenic effect on hypopharyngeal cells is significantly enhanced by pH reduction. 62
31173474 2019
407
A Completely Unique Branching Pattern of the Facial Artery. 62
31942340 2019
408
Increased risk of larynx cancer in patients with gastroesophageal reflux disease from a national sample cohort. 62
30884136 2019
409
Hypopharyngeal cancer treatment: Does initial surgery confer survival benefit? 62
30779398 2019
410
Hypopharyngeal cancer risk in Japanese: Genetic polymorphisms related to the metabolism of alcohol- and tobacco-associated carcinogens. 62
31169220 2019
411
Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy. 62
30737970 2019
412
Clinical Predictors of Laryngeal Preservation Rate in Stage III-IV Laryngeal Cancer and Hypopharyngeal Cancer Patients Treated with Organ Preservation. 62
31350965 2019
413
Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer. 62
31222167 2019
414
Impact of retropharyngeal lymph node dissection in the surgical treatment of hypopharyngeal cancer. 62
30620443 2019
415
Metabolic tumor volume of metastatic lymph nodes and survival after total laryngectomy in laryngeal and hypopharyngeal cancer. 62
31109690 2019
416
Risk factors for cervical lymph node metastasis in endoscopically resected superficial hypopharyngeal cancers. 62
30249511 2019
417
[Characteristics of cervical lymph node metastasis of cN0 laryngeal carcinoma]. 62
31137093 2019
418
Differential impact of age on survival in head and neck cancer according to classic Cox regression and decision tree analysis. 62
30578588 2019
419
Radiomics features analysis of PET images in oropharyngeal and hypopharyngeal cancer. 62
31045814 2019
420
Effects of occupational status on social adjustment after laryngectomy in patients with laryngeal and hypopharyngeal cancer. 62
30927102 2019
421
Validation of reference genes for the normalization of RT-qPCR expression studies on human laryngeal cancer and hypopharyngeal cancer. 62
31173291 2019
422
Surgical management around the paratracheal area of hypopharyngeal cancer. 62
30811540 2019
423
Cost analysis of office-based transnasal esophagoscopy. 62
30806806 2019
424
Surgery is not the only determinant of an outcome in patients with hypopharyngeal carcinoma. 62
30791162 2019
425
Elective neck treatment during salvage (pharyngo) laryngectomy. 62
30610371 2019
426
Upregulation of microRNA‑194‑5p inhibits hypopharyngeal carcinoma cell proliferation, migration and invasion by targeting SMURF1 via the mTOR signaling pathway. 62
30720112 2019
427
Open-neck organ preservation surgery for hypopharyngeal cancer: indications, techniques, limits, and outcomes. 62
30507694 2019
428
Human Bone Marrow Mesenchymal Stem Cells Functionalized by Hybrid Baculovirus-Adeno-Associated Viral Vectors for Targeting Hypopharyngeal Carcinoma. 62
30747033 2019
429
Cortactin as a potential predictor of second esophageal neoplasia in hypopharyngeal carcinoma. 62
30107961 2019
430
[A Nutritional Supplement with a High Blend Ratio of ω-3 Fatty Acids(Prosure®) Reduces Severe Oral Mucositis and Body Weight Loss for Head and Neck Cancer Patients Treated with Chemoradiotherapy]. 62
31164507 2019
431
Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy. 62
30934880 2019
432
Organ Preservation Protocols in T4 Laryngeal Cancer: a Review of the Literature. 62
30948891 2019
433
Organ preservation in laryngeal and hypopharyngeal cancer. 62
30846178 2019
434
Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography evaluation using metabolic tumor volume of the primary tumor and lymph nodes in advanced hypopharyngeal cancer. 62
30536887 2019
435
Hypopharyngeal carcinoma: Do you know your guidelines? 62
30570183 2019
436
[The clinical characteristics and two different treatment outcomes of 321 patients with hypopharyngeal squamous cell carcinoma]. 62
30813702 2019
437
The Limitations of Collagen/CPP Hybrid Peptides as Carriers for Cancer Drugs to FaDu Cells. 62
30769789 2019
438
The Emerging Role of Robotic Surgery among Minimally Invasive Surgical Approaches in the Treatment of Hypopharyngeal Carcinoma: Systematic Review and Meta-Analysis. 62
30781660 2019
439
Using intestinal segments during secondary salvage procedures after failed reconstructions of the cervical oesophagus. 62
30052865 2019
440
Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association. 62
30324861 2019
441
Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases. 62
30732965 2019
442
Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: is the effort worth? 62
30564952 2019
443
The Role of Pretreatment Serum Neutrophil-to-Lymphocyte Ratio in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Pilot Study. 62
30733592 2019
444
MicroRNA‑98/PTEN/AKT pathway inhibits cell proliferation and malignant progression of hypopharyngeal carcinoma by MTDH. 62
30535507 2019
445
Use of MRI and FDG-PET/CT to predict fixation of advanced hypopharyngeal squamous cell carcinoma to prevertebral space. 62
30561113 2019
446
A case report of application of posterior pharyngeal flap in resection and reconstruction of posterior pharyngeal wall carcinomas located at the level of the cricoid cartilage. 62
30762745 2019
447
Long non-coding RNA LOC541471: A novel prognostic biomarker for head and neck squamous cell carcinoma. 62
30675311 2019
448
The Influence of Prediagnosis Alcohol Consumption and the Polymorphisms of Ethanol-Metabolizing Genes on the Survival of Head and Neck Cancer Patients. 62
30275114 2019
449
Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer. 62
30339560 2019
450
The role of acetyl-coA carboxylase2 in head and neck squamous cell carcinoma. 62
31218122 2019
451
Natural History of Treated and Untreated Hypopharyngeal Cancer. 62
30943503 2019
452
Effect of Induction Chemotherapy on Swallowing in Head and Neck Cancer Patients 62
30678386 2019
453
Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. 62
30616782 2019
454
Association of Hospital Volume With Laryngectomy Outcomes in Patients With Larynx Cancer. 62
30476965 2019
455
Consumption of minimally processed foods as protective factors in the genesis of squamous cell carcinoma of the head and neck in Brazil. 62
31344089 2019
456
Impact of age at diagnosis of head and neck cancer on incidence of metachronous cancer. 62
30606157 2019
457
Quality of Life Outcomes following Treatment of Hypopharyngeal Cancer. 62
30943471 2019
458
Systemic Therapy, Palliation and Supportive Care of Patients with Hypopharyngeal Cancer. 62
30943508 2019
459
The effect of ICRT-3 on Wnt signaling pathway in head and neck cancer. 62
30145828 2019
460
Treatment Options for Hypopharyngeal Cancer. 62
30943512 2019
461
Future Perspectives in Hypopharyngeal Cancer Care. 62
30943472 2019
462
Alcohol consumption, tobacco smoking, betel quid chewing and oral health associations with hypopharyngeal cancer among men in Central South China: a case-control study. 62
31372040 2019
463
The Current Indications for Non-Surgical Treatment of Hypopharyngeal Cancer. 62
30754041 2019
464
Metformin Suppresses Hypopharyngeal Cancer Growth by Epigenetically Silencing Long Non-coding RNA SNHG7 in FaDu Cells. 62
30853913 2019
465
Apatinib and S-1 combination therapy for the treatment of advanced head and neck neoplasms: Three case reports. 62
30964124 2019
466
Peripheral Inflammation Markers of Chemosensitivity to Induction Chemotherapy in Hypopharyngeal Cancer Patients. 62
31112985 2019
467
CircRNA-associated ceRNA network reveals ErbB and Hippo signaling pathways in hypopharyngeal cancer. 62
30365065 2019
468
Epidemiology of Hypopharyngeal Cancer. 62
30943510 2019
469
Outcomes of Tumour Control from Primary Treatment of Hypopharyngeal Cancer. 62
30943516 2019
470
Prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer. 62
30537436 2019
471
Surgical Treatment of Advanced Staged Hypopharyngeal Cancer. 62
30943506 2019
472
Symptoms and Signs, Staging and Co-Morbidity of Hypopharyngeal Cancer. 62
30943511 2019
473
Swallowing and Voice Outcomes following Treatment of Hypopharyngeal Cancer: The Need for Supervised Rehabilitation. 62
30754043 2019
474
Sequelae and Complications of Treatment for Hypopharyngeal Cancer: Minimising the Risks. 62
30754042 2019
475
Salvage Treatment Options after Failed Primary Treatment of Hypopharyngeal Cancer. 62
30943500 2019
476
Treatment Options for Hypopharyngeal Cancer in Developing Countries in Africa/South America/Asia. 62
30943517 2019
477
Primary Treatment of T1-T2 Hypopharyngeal Cancer: Changing Paradigms. 62
30943502 2019
478
Clinical and Radiological Evaluation of Hypopharyngeal Carcinoma. 62
30943514 2019
479
Determinants of Free Fasciocutaneous Flap Outcomes in Partial Hypopharyngeal Defects. 62
30422843 2019
480
Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. 62
30663475 2018
481
The Expression of SOCS and NF-ϰB p65 in Hypopharyngeal Carcinoma. 62
30788302 2018
482
The impact of surgical margin status on the outcomes of locally advanced hypopharyngeal squamous cell carcinoma treated by primary surgery. 62
30691335 2018
483
Photothermal therapy with AuNRs and EGFRmAb-AuNRs inhibits subcutaneous transplantable hypopharyngeal tumors in nude mice. 62
30221691 2018
484
Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population-based study. 62
30479063 2018
485
Postoperative Complication Assessments of Different Reconstruction Procedures after Total Pharyngolaryngoesophagectomy: Tubular Gastric Pull-Up versus Whole Gastric Pull-Up. 62
30606350 2018
486
Objective and subjective hyposalivation after treatment for head and neck cancer: Long-term outcomes. 62
30325025 2018
487
[Comparative analysis of clinical efficacies between induction chemotherapy and surgery combined with radiotherapy or concurrent chemoradiotherapy in advanced hypopharyngeal carcinoma]. 62
30585004 2018
488
Recurrent bacterial translocation from gut and sepsis in Head and neck cancer patients and its prevention by probiotics. 62
30220331 2018
489
Radiotherapy modality as a predictor of survival in hypopharyngeal cancer. 62
30306665 2018
490
Hypopharyngeal cancer: A state of the art review. 62
30409307 2018
491
Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. 62
29860375 2018
492
Digital Video Laryngoscopy and Flexible Endoscopic Biopsies as an Alternative Diagnostic Workup in Laryngopharyngeal Cancer: A Prospective Clinical Study. 62
30192647 2018
493
[The role of elective neck dissection during salvage laryngectomy - a retrospective analysis]. 62
29768641 2018
494
Combined transoral-transhyoid endoscopic approach for hypopharyngeal cancer. 62
29402609 2018
495
Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy. 62
30103154 2018
496
Comparison between open partial laryngectomy with tube-free tracheostomy and total laryngectomy for hypopharyngeal cancer with cartilage invasion. 62
30250561 2018
497
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome. 62
29742291 2018
498
Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer. 62
29397249 2018
499
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. 62
30412221 2018
500
Surgically-Treated Locoregionally Advanced Hypopharyngeal Cancer: Outcomes. 62
30357103 2018
501
[Application of gastric pull up and complex laryngotracheal flap to reconstruct the circumferencial defect after resection of the hypopharyngeal and cervical esophageal cancers]. 62
30293257 2018
502
Fibrinogen and Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hypopharyngeal Squamous Cell Carcinoma. 62
30194184 2018
503
Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014. 62
29447088 2018
504
Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer. 62
30309210 2018
505
An investigation on endoscopic laryngopharyngeal surgery and related outcomes. 62
30302154 2018
506
[Reconstruction of the defect of hypopharyngeal carcinoma with radial forearm free flap without cephalic drainage: one case report]. 62
30293265 2018
507
MG‑132 reverses multidrug resistance by activating the JNK signaling pathway in FaDu/T cells. 62
29901180 2018
508
Verification of HE-based CTV in laryngeal and hypopharyngeal cancer using pan-cytokeratin. 62
30094352 2018
509
To do or not to do: salvage management for hypopharyngeal cancer after chemoradiation therapy. 62
29926175 2018
510
True hypopharyngeal carcinosarcoma: a case report and literature review. 62
29996673 2018
511
Oesophageal causes of dysphagia localised only to the pharynx: Implications for the suspected head and neck cancer pathway. 62
29635757 2018
512
Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis. 62
30098764 2018
513
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma. 62
30139993 2018
514
Pectoralis Major Musculocutaneous Flap With a Midline Sternal Skin Paddle for Head and Neck Reconstruction: A New Design. 62
29762448 2018
515
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer. 62
29271789 2018
516
Intrinsic Oncogenic Function of Intracellular Connexin26 Protein in Head and Neck Squamous Cell Carcinoma Cells. 62
30041406 2018
517
[A case report of hypopharyngeal carcinoma with multicentric Castleman disease]. 62
30550160 2018
518
Clinical factors impacting on late dysphagia following radiotherapy in patients with head and neck cancer. 62
29668302 2018
519
Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas. 62
29744637 2018
520
Staging of Laryngeal and Hypopharyngeal Cancer: Computed Tomography versus Histopathology. 62
30083524 2018
521
Postoperative mechanical bowel obstruction after pharyngolaryngectomy for hypopharyngeal cancer: Retrospective analysis using a Japanese inpatient database. 62
29537633 2018
522
Human Papillomavirus 16 E6 Induces FoxM1B in Oral Keratinocytes through GRHL2. 62
29443638 2018
523
Biodegradable Zwitterionic Nanogels with Long Circulation for Antitumor Drug Delivery. 62
29947223 2018
524
Bocca's hemipharyngo-total laryngectomy for hypopharyngeal carcinoma to avoid reconstruction with a pedicled flap. 62
29573005 2018
525
Modified Design of Anterolateral Thigh Flap for Total Pharyngolaryngectomy Reconstruction: A Single-Center Experience. 62
29762451 2018
526
The inhibition of c-MYC transcription factor modulates the expression of glycolytic and glutaminolytic enzymes in FaDu hypopharyngeal carcinoma cells. 62
29790697 2018
527
Photothermal treatment with EGFRmAb-AuNPs induces apoptosis in hypopharyngeal carcinoma cells via PI3K/AKT/mTOR and DNA damage response pathways. 62
29718150 2018
528
[Cause analysis of one case multiply misdiagnosed patient with hypopharyngeal carcinoma]. 62
29921064 2018
529
A case of adult congenital laryngeal cleft asymptomatic until hypopharynx cancer treatment. 62
28943051 2018
530
Poor oral intake causes enteral nutrition dependency after concomitant chemoradiotherapy for pharyngeal cancers. 62
29610959 2018
531
Boerhaave syndrome due to hypopharyngeal stenosis associated with chemoradiotherapy for hypopharyngeal cancer: a case report. 62
29884971 2018
532
Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients. 62
29983029 2018
533
A rare case of secondary small bowel volvulus laparoscopically repositioned: literature review and classification. 62
29946749 2018
534
NF-κB inhibition reverses acidic bile-induced miR-21, miR-155, miR-192, miR-34a, miR-375 and miR-451a deregulations in human hypopharyngeal cells. 62
29516639 2018
535
Dietary inflammatory index and risk of upper aerodigestive tract cancer in Japanese adults. 62
29844870 2018
536
[Treatment and prognosis of 264 patients with hypopharyngeal carcinoma]. 62
29764015 2018
537
[A retrospective study on combined modality therapy with or without surgery for advanced hypopharyngeal squamous cell carcinoma: an analysis of 119 cases]. 62
29764016 2018
538
Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments. 62
29891019 2018
539
[Emphasis on expert consensus guidance for constantly promoting the levels of diagnosis and treatment of hypopharyngeal cancer in China]. 62
29764012 2018
540
[Significance of retropharyngeal node dissection in treatment of hypopharyngeal carcinoma]. 62
29764017 2018
541
The diagnostic role of diffusion-weighted magnetic resonance imaging in hypopharyngeal carcinoma. 62
29552192 2018
542
Downregulation of RNA binding motif protein 17 expression inhibits proliferation of hypopharyngeal carcinoma FaDu cells. 62
29552202 2018
543
A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. 62
29086129 2018
544
Modified TALK Score for Japanese Patients with Laryngeal and Hypopharyngeal Cancers to Predict the Possibility of Laryngeal Preservation by Concurrent Chemoradiotherapy. 62
29955023 2018
545
Occupational exposure to petroleum-based and oxygenated solvents and hypopharyngeal and laryngeal cancer in France: the ICARE study. 62
29621977 2018
546
Salvage surgery for recurrence of laryngeal and hypopharyngeal squamous cell carcinoma: A retrospective study from 2005 to 2013. 62
29198646 2018
547
Impact of alcohol dehydrogenase-aldehyde dehydrogenase polymorphism on clinical outcome in patients with hypopharyngeal cancer. 62
29286190 2018
548
Olfactory and gustatory functions after free flap reconstruction and radiotherapy for oral and pharyngeal cancer: a prospective follow-up study. 62
29380039 2018
549
A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. 62
29866601 2018
550
Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy. 62
29270811 2018
551
Clinicopathological Factors of Cervical Nodal Metastasis and the Concept of Selective Lateral Neck Dissection in the Surgical Management of Carcinoma Larynx and Hypopharynx and Its Outcome. 62
29563730 2018
552
Efficacy of the myofascial pectoralis major flap in the reduction of salivary fistulas after salvage total laryngectomy. 62
28865840 2018
553
Images in Anesthesiology: Tracheopharyngeal Fistula from Treated Hypopharyngeal Carcinoma. 62
28837434 2018
554
[Microvascular reconstruction of the larynx following total laryngectomy]. 62
29186749 2018
555
Predictors of post-treatment stenosis in cervical esophageal cancer undergoing high-dose radiotherapy. 62
29467556 2018
556
Association of eIF4E and SPARC Expression with Lymphangiogenesis and Lymph Node Metastasis in Hypopharyngeal Cancer. 62
29374693 2018
557
Hypopharyngeal cancer associated with synchronous oesophageal cancer: risk factors and benefits of image-enhanced endoscopic screening. 62
29237517 2018
558
Evaluation of coexistence of cancer and active tuberculosis; 16 case series. 62
29204340 2018
559
High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. 62
29378571 2018
560
Correlation between Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer. 62
30092593 2018
561
Analysis of Site-Specific Methylation of Tumor-Related Genes in Head and Neck Cancer: Potential Utility as Biomarkers for Prognosis. 62
29361757 2018
562
c-Jun and Camk2a contribute to the drug resistance of induction docetaxel/cisplatin/5-fluorouracil in hypopharyngeal carcinoma. 62
31949859 2018
563
Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma. 62
30319973 2018
564
Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in 18F-FDG PET in Squamous Cell Carcinoma of the Head and Neck. 62
29311707 2018
565
The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma. 62
30410362 2018
566
Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. 62
29080963 2018
567
Prognostic nutritional index relevance in chemoradiotherapy for advanced oral cavity, oropharyngeal and hypopharyngeal cancer. 62
30272847 2018
568
In vitro cytotoxicity of GO-DOx on FaDu squamous carcinoma cell lines. 62
29593407 2018
569
Transoral laser microsurgery as standard approach to hypopharyngeal cancer. Survival analysis in a hospital based population. 62
28190450 2018
570
Oncological and Functional Evaluation of Open Conservation Surgery for Hypopharyngeal Cancer with/without Reconstruction. 62
29780420 2018
571
Expression of protocadherin8: Function as a tumor suppressor in hypopharyngeal carcinoma. 62
29865037 2018
572
Value of two-cycle docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy in hypopharyngeal carcinoma. 62
29368529 2018
573
Usefulness of ultrasound for assessing the primary tumor of hypopharyngeal carcinoma. 62
29299513 2017
574
[The clinical anatomy of the inferior thyroid arteries and veins and the safety of the modified tracheotomy]. 62
29798394 2017
575
[Study on the metastatic sequence of cervix lymph node in hypopharyngeal carcinoma]. 62
29262512 2017
576
Oncological results of surgical treatment versus organ-function preservation in larynx and hypopharynx câncer. 62
29489975 2017
577
Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy. 62
28624863 2017
578
The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy. 62
29259311 2017
579
Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer. 62
29284434 2017
580
The Second-Look Procedure for Transoral Videolaryngoscopic Surgery for T1 and T2 Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer Patients: Protocol for a Nonrandomized Clinical Trial. 62
29208591 2017
581
Utility of chemoradioselection for the optimization of treatment intensity in advanced hypopharyngeal and laryngeal carcinoma. 62
29285357 2017
582
[Platysma myocutaneous flaps in reconstruction of defects caused by hypopharyngeal cancer resection]. 62
29798390 2017
583
Successful salvage for the intractable massive chylous leakage in a cirrhotic patient: A case report and literature review. 62
29245340 2017
584
Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: a dose-response meta analysis of prospective cohort studies. 62
29228752 2017
585
Lentivirus-mediated RNA interference inhibits the tumorigenicity of cluster of differentiation 44+ tumor cells in hypopharyngeal cancer. 62
29113169 2017
586
E26 Transformation-Specific Transcription Factor ETS2 as an Oncogene Promotes the Progression of Hypopharyngeal Cancer. 62
29111780 2017
587
Results of total laryngectomy as treatment for locally advanced hypopharyngeal cancer. 62
28110860 2017
588
Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. 62
28542679 2017
589
[The clinical curative strategies of hypopharyngeal carcinoma]. 62
29798134 2017
590
Anticancer Effects of Colchicine on Hypopharyngeal Cancer. 62
29061810 2017
591
A modified endoscopic submucosal dissection for a superficial hypopharyngeal cancer: a case report and technical discussion. 62
29110635 2017
592
Downregulation of Calcium-Binding Protein S100A9 Inhibits Hypopharyngeal Cancer Cell Proliferation and Invasion Ability Through Inactivation of NF-κB Signaling. 62
28276321 2017
593
Pyruvate diminishes the cytotoxic activity of ascorbic acid in several tumor cell lines in vitro. 62
28958933 2017
594
Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach. 62
28787757 2017
595
Whole-exome sequencing reveals novel mutations and epigenetic regulation in hypopharyngeal carcinoma. 62
29156722 2017
596
Risk factors for wound complications in head and neck reconstruction: 773 free jejunal reconstruction procedures after total pharyngolaryngoesophagectomy. 62
28736943 2017
597
Survival benefit of surgical approach for advanced oropharyngeal and hypopharyngeal cancer: A retrospective analysis. 62
28691358 2017
598
Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer. 62
29018502 2017
599
Abnormal expression of HAX‑1 is associated with cellular proliferation and migration in human hypopharyngeal squamous cell carcinoma. 62
28791389 2017
600
[Risk factors and survival analysis for synchronous esophageal carcinoma in patients with hypopharyngeal carcinoma]. 62
29050092 2017
601
Current status of superficial pharyngeal squamous cell carcinoma in Japan. 62
28501947 2017
602
[A study of 16 cases on the island pectoralis major muscle flap in repair for the defects after the laryngeal function reserved operation of hypopharyngeal carcinoma]. 62
29797953 2017
603
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer. 62
29070993 2017
604
Comparison of the outcomes of free jejunal flap reconstructions of pharyngoesophageal defects in hypopharyngeal cancer and corrosive injury patients. 62
27880017 2017
605
Transoral robotic total laryngopharyngectomy and free jejunal flap reconstruction for hypopharyngeal cancer. 62
28720420 2017
606
Application of Ultrasound-guided Core Needle Biopsy in the Diagnosis of T3 or T4 Stage Laryngeal and Hypopharyngeal Cancer. 62
28739753 2017
607
Venous superdrained gastric tube pull-up procedure for hypopharyngeal and cervical esophageal reconstruction reduces postoperative anastomotic leakage and stricture. 62
28575244 2017
608
Salvage Transoral Videolaryngoscopic Surgery for radiorecurrent hypopharyngeal and supraglottic cancer. 62
27856033 2017
609
Prognostic value of lymphovascular invasion of the primary tumor in hypopharyngeal carcinoma after total laryngopharyngectomy. 62
28580699 2017
610
The long-term oncological and functional outcomes of transoral robotic surgery in patients with hypopharyngeal cancer. 62
28688681 2017
611
Transoral laser microsurgery for treatment for hypopharyngeal cancer in 211 patients. 62
28474378 2017
612
Overview of surgery for laryngeal and hypopharyngeal cancer in Ontario, 2003-2010. 62
28593742 2017
613
FDG-PET/CT predicts survival and lung metastasis of hypopharyngeal cancer in a multi-institutional retrospective study. 62
28470631 2017
614
Predictors of readmissions after head and neck cancer surgery: A national perspective. 62
28688676 2017
615
Investigating the Association between Alcohol and Risk of Head and Neck Cancer in Taiwan. 62
28851901 2017
616
Clinicopathologic Findings and Treatment Outcome of Laryngectomized Patients with Laryngeal Cancer and Hypopharyngeal Cancer: An Experience in Thailand 62
28843218 2017
617
Prognostic significance of surgical extranodal extension in head and neck squamous cell carcinoma patients. 62
28430988 2017
618
Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis. 62
28688677 2017
619
AGO2 involves the malignant phenotypes and FAK/PI3K/AKT signaling pathway in hypopharyngeal-derived FaDu cells. 62
28903378 2017
620
Frequent aberrant p53 and Fhit expression in endoscopically resected superficial hypopharyngeal cancer and esophageal cancer. 62
28693209 2017
621
Occupational exposure to chlorinated solvents and risk of head and neck cancer in men: a population-based case-control study in France. 62
28738894 2017
622
Patch esophagoplasty with a free proximal lateral leg flap for focal stricture of the cervical esophagus: A case report. 62
26800296 2017
623
HMGB1 attenuates TGF-β-induced epithelial-mesenchymal transition of FaDu hypopharyngeal carcinoma cells through regulation of RAGE expression. 62
28285361 2017
624
[III. Non-Surgical Treatment Strategy for Locally Advanced Laryngeal and Hypopharyngeal Cancer]. 62
28790260 2017
625
[Head and Neck Tumor Larynx Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer]. 62
28790257 2017
626
Effect of daily fraction size on laryngoesophageal dysfunction after chemoradiation for squamous cell carcinomas of the larynx and hypopharynx. 62
28301066 2017
627
Time-course differential lncRNA and mRNA expressions in radioresistant hypopharyngeal cancer cells. 62
28487500 2017
628
Age-adjusted Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiation therapy. 62
28084858 2017
629
MicroRNA-203 inhibits tumour growth and metastasis through PDPN. 62
27775879 2017
630
Clinical outcomes of transoral videolaryngoscopic surgery for hypopharyngeal and supraglottic cancer. 62
28651556 2017
631
[Treatment of intractable aspiration after partial laryngectomy by cuffed tracheostomy tube with inner cannula]. 62
28635221 2017
632
The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma. 62
27401121 2017
633
Enumeration and molecular characterization of circulating tumor cell using an in vivo capture system in squamous cell carcinoma of head and neck. 62
28729770 2017
634
Single-cycle induction chemotherapy for resectable advanced hypopharyngeal cancer. 62
28062933 2017
635
Intake of meat and fish and risk of head-neck cancer subtypes in the Netherlands Cohort Study. 62
28382514 2017
636
Lymph Node Ratio Predicts Recurrence and Survival for Patients with Resectable Stage 4 Hypopharyngeal Cancer. 62
28130622 2017
637
Primary total laryngectomy and pharyngolaryngectomy in T4 pharyngolaryngeal cancers: Oncologic and functional results and prognostic factors. 62
27988198 2017
638
[Diagnostic value of enhanced CT/MRI for thyroid cartilage invasion by malignant tumor]. 62
28558457 2017
639
Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer. 62
28001302 2017
640
[Transoral radiofrequency coblation surgery for the treatment of hypopharyngeal carcinoma]. 62
28558449 2017
641
[Advances in treatment of locally advanced hypopharyngeal cancer]. 62
29871362 2017
642
Long-term outcomes of type I thyroplasty with silicone implantation: Assessment of excised laryngeal tissue from a patient with secondary hypopharyngeal carcinoma. 62
27543073 2017
643
Impact of the early detection of esophageal neoplasms in hypopharyngeal cancer patients treated with concurrent chemoradiotherapy. 62
25359448 2017
644
Correlation of pretreatment 18F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes. 62
27999896 2017
645
Histologic correlation of VEGF and COX-2 expression with tumor size in squamous cell carcinoma of the larynx and hypopharynx. 62
28489236 2017
646
Potential clinical significance of perioperative levels of mRNA in plasma from patients with cancer of the larynx or hypopharynx. 62
28225552 2017
647
Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI. 62
28259450 2017
648
A Novel Application of Double-Paddle Peroneal Chimeric Flap as External Sentinel Monitor in Hypopharyngeal Reconstruction. 62
28195888 2017
649
Comparison of Salvage Total Pharyngolaryngectomy and Cervical Esophagectomy Between Hypopharyngeal Cancer and Cervical Esophageal Cancer. 62
27714538 2017
650
Upregulation of the long noncoding RNA UCA1 affects the proliferation, invasion, and survival of hypopharyngeal carcinoma. 62
28327194 2017
651
Repair of complex pharyngocutaneous fistula using a staged temporoparietal fascial flap. 62
27916282 2017
652
Asymmetric cationic liposomes designed for heat-activated association with cells. 62
27987456 2017
653
Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer. 62
27617428 2017
654
Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. 62
28033526 2017
655
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy. 62
28179356 2017
656
[18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcomes for oropharyngeal and hypopharyngeal cancer treated with definitive radiotherapy. 62
28303058 2017
657
Indwelling voice prosthesis insertion after total pharyngolaryngectomy with free jejunal reconstruction. 62
28894820 2017
658
Use of the liver maximum function capacity test (LiMAx) for the management of liver resection in cirrhosis - A case of hypopharyngeal cancer liver metastasis. 62
28841541 2017
659
The predictive value of MRI in detecting thyroid gland invasion in patients with advanced laryngeal or hypopharyngeal carcinoma. 62
27520569 2017
660
Strategy and early results of treatment of advanced cervical cancer patients with synchronous cancers observed in PET-CT imaging. 62
29057432 2017
661
Correction: Routine Endoscopy for Esophageal Cancer Is Suggestive for Patients with Oral, Oropharyngeal and Hypopharyngeal Cancer. 62
28107467 2017
662
Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells. 62
27847320 2017
663
Down syndrome critical region 1 positively correlates with angiogenesis in hypopharyngeal cancer. 62
27922696 2017
664
Heterogeneous impact of alcohol consumption according to treatment method on survival in head and neck cancer: A prospective study. 62
27801961 2017
665
The Distribution of Phosphatidylcholine Species in Superficial-Type Pharyngeal Carcinoma. 62
28373982 2017
666
p62/SQSTM1 levels predicts radiotherapy resistance in hypopharyngeal carcinomas. 62
28469960 2017
667
Transoral robotic surgery in the seated position: Rethinking our operative approach. 62
27377239 2017
668
Accuracy of [18Fluorine]-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography-Computed Tomography Response Assessment Following (Chemo)radiotherapy for Locally Advanced Laryngeal/Hypopharyngeal Carcinoma. 62
28659717 2017
669
[Expert consensus on surgery and comprehensive treatment of hypopharyngeal carcinoma]. 62
28104011 2017
670
Ultrasound-Guided Needle Biopsy for Diagnosis of Advanced-Stage Malignancies of the Upper Aerodigestive Tract. 62
30480173 2017
671
Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. 62
27825651 2017
672
A 13-Year Single Institutional Experience with Definitive Radiotherapy in Hypopharyngeal Cancer. 62
28182816 2017
673
Late-onset dysphagia caused by severe spastic peristalsis of a free jejunal graft in a case of hypopharyngeal cancer. 62
27068782 2016
674
Early hypopharyngeal cancer treated with different therapeutic approaches: a single-institution cohort analysis. 62
28030898 2016
675
The survival rate and larynx preservation in elderly cancer patients who received surgical operation: A retrospective cohort study. 62
27871805 2016
676
Application of xenogenic acellular dermal matrix in reconstruction of oncological hypopharyngeal defects. 62
27164947 2016
677
[Reconstruction with free jejuna flap for the defect after removal of hypopharyngeal and cervical esophageal caneer: clinical analyses of 103 cases]. 62
27978881 2016
678
Clinical Outcomes of Definitive and Postoperative Radiotherapy for Stage I-IVB Hypopharyngeal Cancer. 62
27919985 2016
679
Hypopharyngeal cancer masquerading as a thyroid mass. 62
28087965 2016
680
Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. 62
28105346 2016
681
Lymph node ratio predicts survival in hypopharyngeal cancer with positive lymph node metastasis. 62
27372745 2016
682
Elevated AEG-1 expression in macrophages promotes hypopharyngeal cancer invasion through the STAT3-MMP-9 signaling pathway. 62
27793010 2016
683
Validated guidelines for tumor delineation on magnetic resonance imaging for laryngeal and hypopharyngeal cancer. 62
27607138 2016
684
Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. 62
27669504 2016
685
Risk factors of thrombosis in a single method of microsurgical head and neck reconstruction: A multi-institutional study of 773 reconstructions with a free jejunal graft after total pharyngolaryngoesophagectomy for hypopharyngeal cancer. 62
27227353 2016
686
A Case of Immunogloblin A Vasculitis Caused by Infection in Tracheotomy Wound. 62
30035520 2016
687
Circulating vitamin D in relation to cancer incidence and survival of the head and neck and oesophagus in the EPIC cohort. 62
27812016 2016
688
Pectoralis major myofascial interposition flap prevents postoperative pharyngocutaneous fistula in salvage total laryngectomy. 62
27107580 2016
689
[Metformin inhibits the growth of hypopharyngeal carcinoma xenografts in nude mice model]. 62
29871173 2016
690
[Effects of dihydroartemisinin on the apoptosis of Fadu cells]. 62
29871174 2016
691
[Repeated carotid blowout's rescue experience of a postoperative patient with hypopharyngeal carcinoma]. 62
27938612 2016
692
The effect and mechanism of action of metformin on in vitro FaDu cell proliferation. 62
27688683 2016
693
Corrigendum: Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study. 62
27803615 2016
694
Routine endoscopic screening for synchronous esophageal neoplasm in patients with head and neck squamous cell carcinoma: a prospective study. 62
26471351 2016
695
Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors. 62
26858198 2016
696
Removing the Taboo on the Surgical Violation (Cut-Through) of Cancer. 62
27468162 2016
697
[Significance of induction chemotherapy in the treatment of locally advanced laryngeal cancer and hypopharyngeal cancer]. 62
29871138 2016
698
[Comparing the free fasciocutaneous flap with free jejunium in reconstruction for hypopharyngeal and cervical esophageal defects]. 62
29871115 2016
699
Evaluation of health-related quality of life with EORTC QLQ-C30 and QLQ-H&N35 in Romanian laryngeal cancer patients. 62
26511987 2016
700
Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo. 62
27484725 2016
701
Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program. 62
26395117 2016
702
Long-term update of the 24954 EORTC phase III trial on larynx preservation. 62
27494036 2016
703
(125)I Seed Permanent Implantation as a Palliative Treatment for Stage III and IV Hypopharyngeal Carcinoma. 62
27440132 2016
704
T-status and an oral fluoropyrimidine, S-1, adjuvant chemotherapy are prognostic factors in reduced-RADPLAT for resectable hypopharyngeal cancer. 62
27007816 2016
705
Reconstruction of hypopharyngeal non-circumferential defects with a submental island flap after hypopharyngeal carcinoma ablation, our experience of 13 cases. 62
26294419 2016
706
Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study. 62
27536177 2016
707
[Human papilloma viruses: other risk factor of head and neck carcinoma]. 62
27325173 2016
708
Hypopharyngeal cancer: looking back, moving forward. 62
27536170 2016
709
Impact of total lesion glycolysis measured by 18F-FDG-PET/CT on overall survival and distant metastasis in hypopharyngeal cancer. 62
27446459 2016
710
Histoanatomical characteristics to increase the success in transoral surgery for hypopharyngeal cancer. 62
27010355 2016
711
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer. 62
27061113 2016
712
Selenium-binding protein 1 in head and neck cancer is low-expression and associates with the prognosis of nasopharyngeal carcinoma. 62
27583873 2016
713
Neurologic late effects associated with radiologic evidence of vertebral osteoradionecrosis after salvage laryngectomy: A syndrome associated with survivors of laryngeal and hypopharyngeal cancer. 62
27080049 2016
714
Free flap combined with pectoralis major flap for reconstruction after total laryngopharyngectomy in patients with advanced hypopharyngeal carcinoma. 62
27066846 2016
715
Curative treatment of head and neck squamous cell carcinoma : Organ preservation strategies in clinical routine in German-speaking countries. 62
27357174 2016
716
Non-surgical organ preservation strategies for locally advanced laryngeal tumors: what is the Italian attitude? Results of a national survey on behalf of AIRO and AIOM. 62
27290695 2016
717
CD271 regulates the proliferation and motility of hypopharyngeal cancer cells. 62
27469492 2016
718
Trends in the Detail of the Stage and Survival Rate in Hypopharyngeal Cancer over 20 Years. 62
30051976 2016
719
[Principles and stragegies in the management of post-therapeutic recurrence of hypopharyngeal cancer]. 62
27480310 2016
720
Paratracheal lymph node dissection, in which patients should it be performed? 62
27405076 2016
721
[Clinical application of thoracoacromial artery perforator flap for hypopharyngeal reconstruction]. 62
30044560 2016
722
[Pharyngoesophageal Reconstruction Using a Laryngotracheal Flap Following Resection for Hypopharyngeal Cancer]. 62
30010290 2016
723
Toenail selenium status and risk of subtypes of head-neck cancer: The Netherlands Cohort Study. 62
27082137 2016
724
[The clinical characteristics and treatment outcomes of 386 patients with hypopharyngeal cancer]. 62
27345879 2016
725
Transoral robotic surgery for early T classification hypopharyngeal cancer. 62
26559383 2016
726
Evaluation of Cases Who Underwent Reconstruction Through Pectoralis Major Myocutaneous Flap after Laryngopharyngectomy. 62
29392018 2016
727
Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base. 62
27019213 2016
728
Chemoselection combined with alternating chemoradiotherapy or surgery for hypopharyngeal cancer. 62
26536058 2016
729
Comparison of Oncological and Functional Outcomes between Initial Surgical versus Non-Surgical Treatments for Hypopharyngeal Cancer. 62
26786092 2016
730
Change in the Quality of Life in Oropharyngeal, Laryngeal and Hypopharyngeal Cancer Patients treated with Volumetric Modulated Arc-Based Concomitant Boost Radiotherapy. 62
27250886 2016
731
Risk factors for late dysphagia after (chemo)radiotherapy for head and neck cancer: A systematic methodological review. 62
25532723 2016
732
Hypopharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. 62
27841124 2016
733
[Multi-disciplinary treatment increases the survival rate of late stage pharyngeal, laryngeal or cervical esophageal cancers treated by free jejunal flap reconstruction after cancer resection]. 62
27188615 2016
734
Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. 62
26969811 2016
735
Retrospective analysis of the clinical efficacy of definitive chemoradiotherapy for patients with hypopharyngeal cancer. 62
26826721 2016
736
In vitro model for gastroduodenal reflux-induced nuclear factor-kappaB activation and its role in hypopharyngeal carcinogenesis. 62
26559497 2016
737
Comparison of outcome and toxicity of two different regimes of neoadjuvant chemotherapy followed by external beam radiotherapy in stages III and IV larynx and laryngopharyngeal malignancies in years 2013-2014. 62
27461675 2016
738
[Preliminary study on intravoxel incoherent motion (IVIM) imaging in laryngeal and hypopharyngeal squamous cell carcinoma]. 62
27117359 2016
739
Intratumoral lymphatic vessel density as a predictor of progression-free and overall survival in locally advanced laryngeal/hypopharyngeal cancer. 62
25641342 2016
740
Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. 62
26920665 2016
741
Pharyngocutaneous fistula and delay in free oral feeding after pharyngolaryngectomy for hypopharyngeal cancer. 62
25784493 2016
742
Oncologic outcome of hypopharyngeal carcinoma treated with different modalities at 2 different university hospitals. 62
25491424 2016
743
Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. 62
27122225 2016
744
[miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression]. 62
27033573 2016
745
Pretreatment Intra-Voxel Incoherent Motion Diffusion-Weighted Imaging (IVIM-DWI) in Predicting Induction Chemotherapy Response in Locally Advanced Hypopharyngeal Carcinoma. 62
26962824 2016
746
Extent of Salvage Neck Dissection in Advanced Oro- and Hypopharyngeal Cancer. 62
26976987 2016
747
Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience. 62
26597398 2016
748
Neoadjuvant intra-arterial chemotherapy in advanced laryngeal and hypopharyngeal cancer. 62
24175975 2016
749
Voice Outcome in Patients Treated With Endoscopic Laryngopharyngeal Surgery for Superficial Hypopharyngeal Cancer. 62
26976030 2016
750
Swallowing function in patients with vertical hemipharyngolaryngectomy for hypopharyngeal squamous cell carcinoma. 62
25225030 2016
751
[Short-term complications in reconstruction of the postoperative defects with free jejunum graft in patients with pharyngeal, laryngeal or cervical esophageal cancers]. 62
27373029 2016
752
Th1-, Th2-, and Th17-associated cytokine expression in hypopharyngeal carcinoma and clinical significance. 62
26392085 2016
753
Aberrant GRK6 promoter methylation is associated with poor prognosis in hypopharyngeal squamous cell carcinoma. 62
26718636 2016
754
HSV-1 Infection Modulates the Radioresponse of a HPV16-positive Head and Neck Cancer Cell Line. 62
26851010 2016
755
Quality-of-life and functional outcomes following pharyngolaryngectomy: a systematic review of literature. 62
26031311 2016
756
Thyroid Gland Involvement in Carcinoma Larynx and Hypopharynx-Predictive Factors and Prognostic Significance. 62
27042568 2016
757
[Role of Narrow-band imaging endoscopy in the diagnosis of hypopharyngeal carcinoma]. 62
26898865 2016
758
Iliopsoas Abscess Possibly due to Klebsiella pneumoniae Infection after Chemoradiotherapy for Hypopharyngeal Cancer. 62
26989543 2016
759
Definitive Radiotherapy Following Induction Chemotherapy for Hypopharyngeal Cancer: Selecting Candidates for Organ-Preserving Treatment Based on the Response to Induction Chemotherapy. 62
26935442 2016
760
Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. 62
26561556 2016
761
The central role of HOTAIR in the malignancy of CD44+ human hypopharyngeal carcinoma cells. 62
27904706 2016
762
[STIM1 gene silencing suppresses tumor formation of human hypopharyngeal carcinoma cell line FaDu in nude mice]. 62
26791772 2016
763
Interobserver variation among pathologists for delineation of tumor on H&E-sections of laryngeal and hypopharyngeal carcinoma. How good is the gold standard? 62
26073449 2016
764
[Survival Analysis Three-year Follow-up of Pacients with Head and Neck Cancer]. 62
26879062 2016
765
A case of hypopharyngeal cancer with stenosis, perforation, and pyogenic spondylitis development after chemoradiotherapy. 62
26829460 2016
766
Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer. 62
25779363 2016
767
Primary lesser sac myxoid liposarcoma: A case report. 62
27176503 2016
768
Prediction of Lymph Node Metastasis by Tumor Dimension Versus Tumor Biological Properties in Head and Neck Squamous Cell Carcinomas. 62
25761475 2016
769
A Retrospective Study of G-Tube Use in Japanese Patients Treated with Concurrent Chemoradiotherapy for Hypopharyngeal Cancer. 62
27556279 2016
770
mARC Treatment of Hypopharynx Carcinoma with Flat and Flattening-Filter-Free Beam Energies - A Planning Study. 62
27741272 2016
771
The use of matrigel has no influence on tumor development or PET imaging in FaDu human head and neck cancer xenografts. 62
26762341 2016
772
Body mass index and risk of subtypes of head-neck cancer: the Netherlands Cohort Study. 62
26634678 2015
773
Cancer Risk After Pernicious Anemia in the US Elderly Population. 62
26079040 2015
774
Transoral robotic surgery (TORS) for laryngeal and hypopharyngeal cancers. 62
26266762 2015
775
Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer. 62
25933585 2015
776
Erratum to: Intratumor Textural Heterogeneity on Pretreatment ¹⁸F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer. 62
25608773 2015
777
Xenogeneic acellular dermal matrix in combination with pectoralis major myocutaneous flap reconstructs hypopharynx and cervical esophagus. 62
25355034 2015
778
Combined use of gastric pull-up and pectoralis major flaps for massive defects after total laryngopharyngoesophagectomy in patients with advanced hypopharyngeal carcinoma. 62
25488278 2015
779
Lung abscess mimicking lung cancer developed around staples in a patient with permanent tracheostoma. 62
24756239 2015
780
[Free radial forearm flap for reconstruction of head and neck soft tissue defects after tumor resection]. 62
26541847 2015
781
The Role of the Modified Barium Swallow Study and Esophagram in Patients with Globus Sensation. 62
26111741 2015
782
Feasibility and safety of transoral robotic surgery (TORS) for early hypopharyngeal cancer: a subset analysis of the Hamburg University TORS-trial. 62
25217079 2015
783
Clinical implication of computed tomography findings in patients with locally advanced squamous cell carcinoma of the larynx and hypopharynx. 62
25149290 2015
784
[New Combination Therapy to Improve the Functional Preservation Rate of the Larynx in Laryngeal, Oropharyngeal, and Hypopharyngeal Cancers]. 62
26489542 2015
785
[Analysis of clinical factors for the efficacy of TPF in treating hypopharyngeal carcinoma]. 62
26999841 2015
786
Utility of algorithm-based chemoradioselection in the treatment for advanced hypopharyngeal carcinoma. 62
24816950 2015
787
[Flap reconstruction of the surgical defects of hypopharyngeal cancer]. 62
26647528 2015
788
[Retrospective Study of Laryngeal Preservation Treatment for Hypopharyngeal Carcinoma with Transoral Resection or Induction Chemotherapy]. 62
26615662 2015
789
Applied anatomy of the submental island flap and its clinical application in the repair of defects following hypopharyngeal carcinoma resection. 62
29204539 2015
790
Human papillomavirus DNA and p16(INK4a) expression in hypopharyngeal cancer and in relation to clinical outcome, in Stockholm, Sweden. 62
26120094 2015
791
[Clinical characteristics of multiple primary cancer associated with esophageal squamous carcinoma]. 62
26815192 2015
792
Clinical outcomes of synchronous head and neck and esophageal cancer. 62
26484300 2015
793
[Application of improved submental island flap in hypopharyngeal cancer reserved laryngeal function surgery]. 62
26685398 2015
794
Vitamin and carotenoid intake and risk of head-neck cancer subtypes in the Netherlands Cohort Study. 62
26156734 2015
795
Impact of indication-shift of primary and adjuvant chemo radiation in advanced laryngeal and hypopharyngeal squamous cell carcinoma. 62
24961436 2015
796
Intratumor Textural Heterogeneity on Pretreatment (18)F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer. 62
25487968 2015
797
[Consideration on the treatment of hypopharyngeal cancer from the view of NCCN Guideline 2014]. 62
26714608 2015
798
Preservation of laryngeal function improves outcomes of patients with hypopharyngeal carcinoma. 62
24913624 2015
799
Derivation of a clinical decision rule for predictive factors for the development of pharyngocutaneous fistula postlaryngectomy. 62
26145251 2015
800
Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma. 62
25840888 2015
801
[Experience of applying acellular dermal matrix in the head and neck tumor surgery]. 62
26695982 2015
802
Modified Tumor Classification With Inclusion of Tumor Characteristics Improves Discrimination and Prediction Accuracy in Oral and Hypopharyngeal Cancer Patients Who Underwent Surgery. 62
26166107 2015
803
Parathyroid gland autotransplantation after total thyroidectomy in surgical management of hypopharyngeal and laryngeal carcinomas: A case series. 62
25852933 2015
804
[Clinical experience with the supraclavicular flap to reconstruct head and neck defects]. 62
26695797 2015
805
Successful treatment of quintuple primary cancer, including esophageal cancer: A case report. 62
26137110 2015
806
Thyroid dysfunction after intra-arterial chemotherapy for hypopharyngeal and laryngeal cancer. 62
25544714 2015
807
Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review. 62
26246660 2015
808
Hypopharyngeal Carcinoma With Pancreatic Metastasis. 62
26080224 2015
809
[The Radiosensitizing Effect of Resveratrol on Hopypharyngeal Carcinoma Cell Line FADU and its Effect on the Cell Cycle]. 62
26242123 2015
810
Stromal interaction molecule 1 (STIM1) silencing inhibits tumor growth and promotes cell cycle arrest and apoptosis in hypopharyngeal carcinoma. 62
25832866 2015
811
Transoral robot-assisted carbon dioxide laser surgery for hypopharyngeal cancer. 62
25224300 2015
812
Predictors of thyroid gland involvement in hypopharyngeal squamous cell carcinoma. 62
25837190 2015
813
Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. 62
24590756 2015
814
[Application of gastric pharyngeal anastomosis assisted by laparoscope and a report of 4 cases]. 62
26281059 2015
815
Socioeconomic position and stage at diagnosis of head and neck cancer - a nationwide study from DAHANCA. 62
25734503 2015
816
Prevertebral space invasion in head and neck cancer: negative predictive value of imaging techniques. 62
25416240 2015
817
Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck. 62
25832686 2015
818
[Efficacy analysis of sequential surgery after the DCF scheme induction chemotherapy in T2-3 laryngeal carcinoma and hypopharyngeal carcinoma]. 62
26201178 2015
819
Head and neck cancer in South Asia: macroeconomic consequences and the role of surgery. 62
26313106 2015
820
Disease control and clinicopathological prognostic factors of total pharyngolaryngectomy for hypopharyngeal cancer: a single-center study. 62
24870950 2015
821
[Therapeutic effect of submental flap in repairing of approaching circumferential defects after hypopharyngeal cancer ablation with laryngeal function unpreserved]. 62
26201182 2015
822
[The application of double pedicle blood supply pectoralis major myocutaneous flap in reconstruction of laryngeal and hypo pharyngeal defect after carcinoma resection]. 62
26201179 2015
823
[Clinical characteristics of 97 hypopharyngeal carcinoma cases]. 62
26211163 2015
824
Survival trends in hypopharyngeal cancer: a population-based review. 62
25220657 2015
825
Consumption of vegetables and fruits and risk of subtypes of head-neck cancer in the Netherlands Cohort Study. 62
25220255 2015
826
Prognostic factor of severe complications in patients with hypopharyngeal cancer with primary concurrent chemoradiotherapy. 62
25750336 2015
827
Primary and salvage total laryngectomy. Influential factors, complications, and survival. 62
26011346 2015
828
Cancer incidence, trends, and survival among immigrants to Sweden: a population-based study. 62
25599121 2015
829
Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control. 62
25367098 2015
830
PiCO2 monitoring of transferred jejunum perfusion using an air tonometry technique after hypopharyngeal cancer surgery. 62
25789955 2015
831
Clinical significance of early detection of esophageal cancer in patients with head and neck cancer. 62
25167869 2015
832
[Spindle Cell Carcinoma of the Head and Neck: A Report of 6 Cases]. 62
26336792 2015
833
Factors associated with gastrostomy tube dependence after concurrent chemoradiotherapy for hypopharyngeal cancer. 62
25129396 2015
834
Nerve branches to the posterior cricoarytenoid muscle may complicate the laryngeal reinnervation procedure. 62
25267429 2015
835
[Implantable Cardioverter Defibrillator and Perioperative Magnet Application: A Case Report]. 62
26121817 2015
836
[The options of surgery and laryngeal preservation for hypopharyngeal cancer patients more than 65 years old]. 62
26121833 2015
837
Contemporary therapeutic management of locally advanced hypopharyngeal cancer: oncologic and functional outcomes - a report on 100 cases. 62
25578129 2015
838
Heterogeneous bovine acellular dermal matrix for mucosal repair in reconstructive surgery for laryngeal and hypopharyngeal carcinoma. 62
26045024 2015
839
Transoral resection of laryngeal and hypopharyngeal cancer is an established surgical procedure. 62
25377058 2015
840
Voice prostheses, microbial colonization and biofilm formation. 62
25366225 2015
841
Early experience in transoral robotic surgery (TORS) for non-oropharyngeal head and neck malignancies: a review of functional and oncologic outcomes. 62
26891528 2015
842
Feasibility and clinical outcomes of transoral robotic surgery and transoral robot-assisted carbon dioxide laser for hypopharyngeal carcinoma. 62
25478973 2015
843
Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice. 62
25923669 2015
844
Prognostic value of SUVmean in oropharyngeal and hypopharyngeal cancers: comparison with SUVmax and other volumetric parameters of 18F-FDG PET. 62
25423344 2015
845
RbAp48 Is Critical for the Proliferation of Hypopharyngeal Carcinoma. 62
26376479 2015
846
Lateral tarsal artery flap: an option for hypopharyngeal reconstruction in patients with hypopharyngeal carcinomas after surgery. 62
26131060 2015
847
Effect of number and ratio of positive lymph nodes in hypopharyngeal cancer. 62
24347492 2015
848
Subjective voice quality, communicative ability and swallowing after definitive radio(chemo)therapy, laryngectomy plus radio(chemo)therapy, or organ conservation surgery plus radio(chemo)therapy for laryngeal and hypopharyngeal cancer. 62
25348250 2015
849
The accuracy of target delineation in laryngeal and hypopharyngeal cancer. 62
25734331 2015
850
[Long Term Monitoring of Nutritional, Clinical Status and Quality of Life in Head and Neck Cancer Patients]. 62
26062622 2015
851
Radiotherapy and Concurrent Chemo-Radiotherapy in Locally Advanced Hypopharyngeal Cancers--A Hospital Registry Based Analysis. 62
26107231 2015
852
[Two cases of acute pulmonary embolism in head and neck tumor surgery]. 62
25989673 2015
853
Influence of residential environment and lifestyle on multiple primary malignancies in Taiwan. 62
25921174 2015
854
Analysis of preoperative serum levels of MMP1, -2, and -9 in patients with site-specific head and neck squamous cell cancer. 62
25503184 2014
855
[Laryngo-tracheal flap to reconstruct the defect after resection of the hypopharyngeal carcinoma with cervical esophagus involvement]. 62
25895312 2014
856
Clinical significance of intensive endoscopic screening for synchronous esophageal neoplasm in patients with head and neck squamous cell carcinoma. 62
25372595 2014
857
Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. 62
25499638 2014
858
[Expression and effect of microRNA-214 in advanced hypopharyngeal carcinoma]. 62
25623865 2014
859
[Resveratrol enhances radiosensitivity of human hypopharyngeal carcinoma cell line in nude mice]. 62
25413066 2014
860
Gastrostomy dependence in head and neck carcinoma patient receiving post-operative therapy. 62
25145381 2014
861
Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer. 62
24115178 2014
862
[A case of metachronous triple cancer treated with a multimodal approach including surgical resection]. 62
25731413 2014
863
[Total pharyngolaryngoesophagectomy with free jejunal transfer for a patient who previously underwent distal esophagectomy with gastric tube reconstruction via a posterior mediastinal route]. 62
25731397 2014
864
[The clinical value of sentinel lymph node detection in laryngeal and hypopharyngeal carcinoma patients with clinically negative neck by methylene blue method and radiolabeled tracer method]. 62
25735093 2014
865
Giant right ventricular metastasis of hypopharyngeal cancer complicated by ventricular tachycardia and cardiogenic shock. 62
24819849 2014
866
[Prognostic significance of the number of positive lymph nodes, number of involved regions and metastatic lymph node ratio in hypopharyngeal cancer]. 62
25567312 2014
867
Free skin flap reconstruction after partial hypopharyngectomy with laryngeal preservation. 62
24443773 2014
868
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study. 62
24849707 2014
869
Extracellular calcium regulates keratinocyte proliferation and HPV 16 E6 RNA expression in vitro. 62
25295350 2014
870
Multi-modality management for loco-regionally advanced laryngeal and hypopharyngeal cancer: balancing the benefit of efficacy and functional preservation. 62
25131963 2014
871
Hypopharyngeal cancer incidence, treatment, and survival: temporal trends in the United States. 62
25295351 2014
872
Plummer-Vinson syndrome following gastric bypass surgery. 62
25255352 2014
873
Radiotherapy-induced hearing loss in patients with laryngeal and hypopharyngeal carcinomas. 62
25420378 2014
874
Salvage surgery for local residual or recurrent pharyngeal cancer after radiotherapy or chemoradiotherapy. 62
24676876 2014
875
Aerodigestive cancers: pharyngeal cancer. 62
25198383 2014
876
Prognostic significance and association of Helicobacter pylori infection in pharyngolaryngeal cancer. 62